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ABSTRACT 
Advanced therapeutic dressings that take active part in wound healing to achieve rapid and 
complete healing of chronic wounds is of current research interest. There is a desire for novel 
strategies to achieve expeditious wound healing due to the enormous financial burden 
worldwide. This paper reviews the current state of wound healing and wound management 
products, with emphasis on the demand for more advanced forms of wound therapy and some 
of the current challenges and driving forces behind this demand. The paper reviews information 
mainly from peer reviewed literature and other publicly available sources such as the FDA. A 
major focus is the treatment of chronic wounds including amputations, diabetic and leg ulcers, 
pressure sores, surgical and traumatic wounds (e.g. accidents and burns) where patient 
immunity is low and the risk of infections and complications are high. The main dressings 
include medicated moist dressings, tissue engineered substitutes, biomaterials based biological 
dressings, biological and naturally derived dressings, medicated sutures and various 
combinations of the above classes. Finally, the review briefly discusses possible prospects of 
advanced wound healing including some of the emerging approaches such as hyperbaric 
oxygen, negative pressure wound therapy and laser wound healing, in routine clinical care. 
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1.1 Overview 
 Wound healing is a global medical concern with several challenges including the 
increasing incidence of obesity and type II diabetes, an ageing population (especially in 
developed countries with low birth rates) and the requirement for more effective but also cost 
effective dressings.1 Wound healing is a complex process involving several inter-related 
biological and molecular activities for achieving tissue regeneration. The main physiological 
events include coagulation, inflammation and removal of damaged matrix components, 
followed by cellular proliferation and migration, angiogenesis, matrix synthesis and deposition, 
re-epitheliazation and remodeling.2 These are generally classified into five major phases known 
as hemostasis, inflammation, proliferation, migration and remodeling/maturation.1 Wound 
healing and the different phases involved have been extensively discussed in several reviews 
and textbooks and the reader is referred to these for detailed exposition on the molecular and 
physiological basis of the different stages of wound healing.1-9 
 
:RXQGV 
 A wound can be defined as an injury or disruption to anatomical structure and function 
resulting from simple or severe break in the skin and can extend to other tissues and structures 
such as subcutaneous tissue, muscles, tendons, nerves, vessels and even to the bone.1,9,10 Of all 
the body tissues, the skin is definitely the most exposed to damage and easily prone to injury, 
abrasions and burns due to trauma or surgery. The rapid restoration of homeostatic 
physiological conditions is a prerequisite for complete lesion repair, because a slow and 
incorrect repair can cause serious damages including the loss of skin, hair and glands, onset of 
infection, occurrence of skin diseases, injuries to the circulatory system and, in severe cases, 
death of the tissue.  
 Based on the nature of the repair process, wounds can be classified as acute or chronic 
wounds. Acute wounds are usually tissue injuries that heal completely, with minimal scarring, 
within the expected time frame, usually 8±12 weeks.11 The primary causes of acute wounds 
include mechanical injuries due to external factors such as abrasions and tears, which are 
caused by frictional contact between the skin and hard surfaces. Mechanical injuries also 
include penetrating wounds caused by knives and gunshots and surgical wounds caused by 
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incisions, for example to remove tumors. Another category of acute wounds includes burns and 
chemical injuries, which arise from a variety of sources such as radiation, electricity, corrosive 
chemicals and thermal sources. Chronic wounds, on the other hand, arise from tissue injuries 
that heal slowly that have not healed in 12 weeks and often reoccur.5 Chronic wounds are often 
heavily contaminated and usually involve significant tissue loss that can affect vital structures 
such as bones, joints and nerves. Such wounds fail to heal due to repeated trauma to the injured 
area or underlying physiological conditions such as diabetes, persistent infections, poor 
primary treatment and other patient related factors.12 These result in a disruption of the orderly 
sequence of events during the wound healing process.5,13,14 Furthermore, impaired wound 
healing can lead to an excessive production of exudates that can cause maceration of healthy 
skin tissue around the wound.15 
 Wounds are also characterized based on the number of skin layers and area of skin 
affected.16 Injury that affects the epidermal skin surface alone is referred to as a superficial 
wound, whilst injury involving both the epidermis and the deeper dermal layers, including 
blood vessels, sweat glands and hair follicles is referred to as partial thickness wound. Full 
thickness wounds occur when the underlying subcutaneous fat or deeper tissues are damaged 
in addition to the epidermis and dermal layers. Ferreira et al.17 have described both acute and 
FKURQLF ZRXQGV WKDW DUH GLIILFXOW WR KHDO DV µFRPSOH[ ZRXQGV¶ ZLWK XQLTXH FKDUDFWHULVWLFV 
which can be summarized as extensive loss of the integument which comprises skin, hair, and 
associated glands; inIHFWLRQHJ)RXUQLHU¶VJDQJUHQHZKLFKPD\UHVXOWLQWLVVXHORVVtissue 
death or signs of circulation impairment and presence of underlying pathology. 
 Nawaz and Bentley,7 have described some of the factors that contribute towards 
retardation in wound healing (chronic wounds) which are summarized in table 1 below. 
Common chronic skin and soft tissue wounds can be divided into three major groups due to 
similarities in their pathogenesis. These are leg ulcers (of venous, ischemic or of traumatic 
origin), diabetic foot ulcers, and pressure ulcers.18 It also includes other hard-to-heal acute 
wounds such as wounds caused by cancer, pyoderma gangrenosum, immunologic and 
hematologic wounds,19 amputations, abdominal wounds, burns and skin grafts.20 In recent 
years, other more serious forms of chronic wounds such as buruli ulcer, caused by bacterial 
infection which involves significant skin tissue loss, have been reported.21,22 
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Table 1. Local and systemic factors that slow down wound healing.7 
 
Local factors Systemic factors 
x ,QDGHTXDWHEORRGVXSSO\ x 6KRFN 
x :RXQGGHKLVFHQFH x &KURQLFUHQDODQGKHSDWLFIDLOXUH 
x ,QIHFWLRQ x $GYDQFLQJSK\VLRORJLFDODJH 
x ([FHVVORFDOPRELOLW\VXFKDVRYHUD
MRLQW x 2EHVLW\ 
x 3RRUVXUJLFDODSSRVLWLRQRUWHFKQLTXH x 6PRNLQJ 
x ,QFUHDVHGVNLQWHQVLRQ x &KHPRWKHUDS\DQGUDGLRWKHUDS\ 
x 7RSLFDOPHGLFLQHV x 'LDEHWHVPHOOLWXV 
x 3RRUYHQRXVGUDLQDJH x 6\VWHPLFPDOLJQDQF\ 
x 3UHVHQFHRIIRUHLJQERG\RUIRUHLJQ
ERG\UHDFWLRQV 
x ,PPXQRVXSSUHVVDQWVDQWLFRDJXODQWV
FRUWLFRVWHURLGV 
x +HPDWRPD x 9LWDPLQDQGWUDFHHOHPHQWVGHILFLHQF\ 
 
 Venous leg ulcers are triggered by malfunction of venous valves causing venous 
hypertension in the crural veins (veins supplying the leg), which increases the pressure in 
capillaries and results in edema. Venous pressure exceeding 45 mmHg certainly leads to 
development of a venous leg ulcer. Diabetic foot ulcer is triggered by monotonous load on the 
neuropathic and often ischemic foot while pressure ulcers are caused by sustained or repetitive 
load on often vulnerable areas such as the sciatic (spinal nerve roots), tuberculum, sacral area, 
heels, and shoulders in the immobilized patient.23 Patients with chronic ulcers usually present 
with underlying complicated factors caused by immunological defects, dysfunction in diabetic 
¿EUREODVWVDQG WKHHIIHFWRI ORFDO LQIHFWLRQRU FULWLFDO FRORQL]DWLRQDQGGLVUXSWLYHHIIHFWVRf 
bacteria in the form of increased cytokine cascades that prolong the inflammatory phase by 
FRQWLQXRXV LQÀX[ RI SRO\PRUSKRQXFOHDU QHXWURSKLOV ZKLFK UHOHDVH F\WRWR[LF HQ]\PHV IUHH
R[\JHQ UDGLFDOV DQG LQÀDPPDWRU\ PHGLDWRUV 7KHVH IDFWRUV DUH UHVSRQVLEOH Ior cellular 
dysfunction and damage to the host tissue,24 which cause delays or stop completely, the wound 
healing process.25 The physiological basis of chronic wound evolution is complex. Continuous 
migration of neutrophils into the wound area causes raised levels of the destructive proteins 
called matrix metallo-proteinases (MMPs) 26-28 including MMP-8 and neutrophil-derived 
elastase. This is in contrast to normal healing wounds in which excess levels of matrix metallo-
SURWHLQDVHV 003V DUH LQKLELWHG WKURXJK WKH QRQVSHFLILF SURWHLQDVH LQKLELWRU Į-
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macroglobulin and the more specific tissue inhibitors of matrix metalloproteinases (TIMMP)29. 
In chronic wounds, the ratio of the harmful MMP (to the protective TIMMP is raised, resulting 
in the degradation of extracellular matrix30-32, changes in the cytokine profile, and reduced 
levels of proliferative factors required for effective healing .33,34  Table 2 summarizes the 
different types of chronic wounds commonly encountered in clinical management whilst figure 
1 shows photographic representation of the four most common chronic wounds commonly 
reported. 
 
 
Figure 1. (A) Arterial ulcer at the cross malleolus of the leg with sharp margins and a punched out appearance; 
(B) Venous stasis ulcer with irregular border and shallow base, (C) Diabetic foot ulcer with surrounding callus, 
severe ulcer caused by diabetic neuropathy and bony deformity; (D) Pressure ulcer in a paraplegic (impairment 
of motor or sensory function in the lower extremities) patient, causing full-thickness skin loss (Adapted from 
Fonder et al., 2008; with permission).35 
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Table 2. The major chronic wounds commonly encountered in clinical wound therapy 
Type of Ulcer Description Risks factors Symptoms 
Diabetic Ulcers Diabetic foot ulcers (also known as neuropathic 
ulcers) are a major complication of diabetes mellitus. 
The most common cause is uncontrolled blood 
glucose (sugars) over a prolonged period of 
time.  Two other disorders, diabetic neuropathy and 
peripheral vascular disease, can also contribute to 
ulcer formation. 
 Uncontrolled blood sugars 
 Diabetic peripheral neuropathy 
 Peripheral vascular disease 
Diabetic ulcers usually present on the foot at an area of trauma or a 
weight-bearing surface.  The wound bed is commonly dry and may 
have necrotic tissue or a foul odor. This kind of ulcer may be a small 
wound area on the outside but can hide an underlying abscess. The 
skin around the wound commonly has hyperkeratosis. These ulcers are 
generally painless due to altered sensation or neuropathy. 
Pressure Ulcers Pressure ulcers, also known as decubitus ulcers or bed 
sores, occur in people with conditions that limit or 
inhibit movement of body parts that are commonly 
subjected to pressure, such as the sacrum and heels. A 
pressure ulcer is an area of skin that deteriorates when 
the skin is exposed to prolonged pressure.  This 
prolonged and unrelieved pressure restricts blood flow 
into the area and tissue damage or tissue death results. 
 Patients confined to wheelchair or bed  
 Increased age 
 Mental or physical deficits that affect their 
ability to move 
 Chronic conditions that prevent areas of the 
body from receiving proper blood flow 
 Fragile skin (patient under steroidal 
therapy), urinary or fecal incontinence 
 Malnutrition 
A pressure ulcer generally starts as reddened area on the skin and, if 
the contributing pressure is unrelieved, the ulcer progresses to a 
blister, then an open sore, and finally a deep crater. This deterioration 
may occur rapidly. The most common places for pressure ulcers to 
form are over bones close to the skin, such as the sacrum, heels, 
elbows, hips, ankles, shoulders, back, and back of the head. Pressures 
sores are categorized from stage I (earliest signs) to stage IV (worst) 
according to severity and the treatments depend on the wound 
stage. Two additional stages can be used in case of severe wounds. 
They are ³unstageable´ and ³suspected deep tissue injury´. 
Venous ulcers Venous ulcers, also known as vascular or stasis ulcers, 
develop as a consequence of venous 
insufficiency.  The damaged valves allow blood to 
pool in the vein, and as the vein overfills, blood may 
leak out into the surrounding tissue leading to a 
breakdown of the tissue and development of a skin 
ulcer.  Venous ulcers commonly occur on the sides of 
the leg, above the ankle and below the knee. 
 Deep vein thrombosis 
 Obesity or poor nutrition 
 Pregnancies 
 A family history of varicose veins 
 Smoking and excessive alcohol use 
 The lack of physical activity 
 Aging 
 Work that requires prolonged standing 
more 
The first sign of a venous skin ulcer is skin that turns dark red or 
purple over the area where the blood is leaking out of the vein. The 
wound bed is often beefy red and may bleed easily. The ulcer may be 
painful.  Necrotic tissue, slough (yellow, tan, grey, green, or brown) 
and/or eschar (tan, brown, or black), may also be present. The skin 
may also become thick, dry, and itchy. Venous ulcers are commonly 
slow to heal and often require lifetime modifications to prevent re-
development. 
Arterial ulcers  Arterial ulcers result from a complete or partial 
blockage in the arteries.  They are almost always 
caused by atherosclerosis. In this pathology, 
cholesterol or other fatty plaques settle in the arteries 
causing obstructions which result in poor blood 
circulation. This poor circulation leads to tissue death 
and ulcer formation.  
 Trauma 
 Limited joint mobility 
 Increased age 
 Diabetes mellitus 
 High blood pressure 
 Arteriosclerosis 
 Peripheral vascular disease 
Wounds commonly have minimal drainage and are often very 
painful.  Pain is often relieved by dangling legs and increased when 
legs are elevated. 
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7KHQHHGIRUDGYDQFHGGUHVVLQJV 
  Wound dressings are traditionally used to protect the wound site from contamination36 
but they can be exploited as platforms to deliver bioactive molecules to wound sites. The use 
of topical bioactive agents in the form of solutions, creams and ointments for drug delivery to 
the wound is not very effective as they rapidly absorb fluid, and in the process lose their 
rheological characteristics and become mobile.1 For this reason, the use of solid wound 
dressings is preferred in the case of exudative wounds as they provide better exudate 
management and prolonged residence at the wound site. Unlike traditional dressings such as 
gauze and cotton wool that take no active part in the wound healing process, advanced dressings 
are designed to have biological activity either on its own or the release of bioactive constituents 
(drugs) incorporated within the dressing1. The incorporated drugs can play an active role in the 
wound healing process either directly as cleansing or debriding agents for removing necrotic 
tissue, or indirectly as antimicrobial drugs, which prevent or treat infection or growth agents 
(factors) to aid tissue regeneration. In chronic wound management, where patients usually 
undergo long treatments and frequent dressing changes, a system that delivers drugs to a wound 
site in a controlled fashion can improve patient compliance and therapeutic outcomes. 
Bioadhesive, polymeric (synthetic, semi-synthetic or naturally derived) dressings are 
potentially useful in the treatment of local infections where it may be beneficial to achieve 
increased local concentrations of antibiotics while avoiding high systemic doses thus reducing 
patient exposure to an excess of drug beyond that required at the wound site.37  
 Composite dressings comprising both synthetic and naturally occurring polymers have 
also been reported for controlled drug delivery to wound sites.1 By controlling the degree of 
swelling, crosslinking density, and degradation rate, delivery kinetics can be tailored according 
to the desired drug release schedule.38 Drug release from polymeric formulations is controlled 
by one or more physical processes including (a) hydration of the polymer by fluids, (b) swelling 
to form a gel, (c) diffusion of drug through the polymer matrix and (d) eventual 
degradation/erosion of the polymeric system.37,39,40 Upon contact of a dry polymeric dressing 
with a moist wound surface, wound exudate penetrates into the polymer matrix. This causes 
hydration and eventually swelling of the dressing to form a release system over the wound 
surface (figure 2). In certain wound dressings, the mechanism for drug release has been 
explained by the hydrolytic activity of enzymes present in the wound exudates41 or from 
bacteria in the case of infected wounds.42 
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Figure 2. Schematic diagrams illustrating the movement of exudate into and drug release from swollen 
bioactive dressings during wound healing. 
'UHVVLQJPDWHULDOV 
 Polymeric materials employed in the formulation of wound dressings can be broadly 
divided into natural inert, natural bioactive and synthetic polymers. A brief overview of these 
categories of polymers used in wound healing and associated references are summarized in 
table 3 and briefly discussed below. However, for a detailed description about the use of these 
materials in wound healing, the reader is referred to the recent review article by Mogosaanu et 
al.43 
Table 3. Summary of the different type of polymers used in commonly used dressings. 
Natural Carboxymethylcellulose69-71  
Bacterial cellulose44,72-74  
Silk fibroin75-77  
Pectin78,79  
Carrageenan80-82  
Synthetic Poly(ethylene oxide)80-83  
Poly(vinyl alcohol) (PVA)84-87  
Poly-L-lactic acid88-90  
Healthy skin area
Wounded area
Drug loaded dressing
Exudate absorption
Swollen dressing
Healthy skin area
Healthy skin area
Swollen dressing
Released drug
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Poly(ethylene glycol)61,91,92  
Polyurethane60,93,94  
Bioactive Collagen95,96  
Gelatin97,98  
Hyaluronic acid53,54,99,100  
Chitosan101-104  
Sodium alginate105-108  
 
1DWXUDOLQHUWSRO\PHUV 
 Natural polymers can be obtained from plant, bacterial, fungal, or animal sources and 
are commonly used due to their biocompatibility and biodegradability. Bacterial cellulose is a 
pure natural exopolysaccharide produced by specific microbial genera. The good 
biocompatibility, hemocompatibility, mechanical strength, microporosity and biodegradability 
make this material one of the most trending natural polymeric materials used for wound care.44 
Bacterial cellulose is used especially as a healing scaffold/matrix for chronic wound dressings 
because it possesses many of the characteristics of an ideal wound dressing. It is known to 
promote autolytic debridement, reduce pain and accelerate granulation, ensuring effective 
wound healing. 45 Furthermore, therapeutically active wound dressings with modified cellulose 
can be prepared by co-immobilization with different active molecules such as enzymes, 
antioxidants, hormones, vitamins and antimicrobial drugs.44 Silk fibroin is another natural 
biopolymer with a highly repetitive amino acid sequence, which leads to the formation of a 
biomaterial with remarkable mechanical and biological characteristics. The unique properties 
of biocompatibility, biodegradability, flexibility, adherence, and absorption of exudates with 
minimal inflammatory reaction make silk a very promising material for wound dressings.46 
Other examples of natural polymers employed in wound dressings include carrageenan, 
carboxymethylcellulose and pectin. 
 
1DWXUDOELRDFWLYHSRO\PHUV 
 Bioactive polymers are also commonly used due to their biocompatibility and 
biodegradability but more importantly, they have an active therapeutic effect on one or more 
stages of wound healing. Most of them form part of the natural body matrix or contain 
components that possess physiological activity as part of the natural wound healing process. 
The most common bioactive polymer dressing materials include collagen (and gelatine), 
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hyaluronic acid, chitosan and sodium alginate.  
 Sodium alginate probably has the largest number of applications in biomedical science 
and bioengineering due to its biocompatibility, bioresorption and ease of gelation. Alginate is 
typically used in the form of a hydrogel in biomedicine, including wound healing, drug delivery 
and tissue engineering applications.38  
The most common method to prepare hydrogels from an aqueous alginate solution is to 
combine with an ionic cross-linking agent such as divalent cations (e.g. Ca2+). The interaction 
occurs between G-rich regions of adjacent polymer chains resulting in the formation of a bulk 
VWUXFWXUHLQDVKDSHRIDQµHJJ-ER[¶47 The composition in the guluronic segments (molecular 
weight and M/G ratio) and the extent of cross-linking will largely affect the quality of the 
matrices formed. When hydrogels are made from alginate rich in guluronic acid residues, the 
resulting gels tend to be rigid, while more elastic gels are produced from alginates with ORZĮ-
l-guluronic acid content.48 The ability of calcium ions (Ca2+) to form crosslinks with alginate 
makes calcium alginate dressings ideal materials as scaffolds for tissue engineering.49  
 
Alginate based absorbent wound dressings may be used on multiple wound types, including 
pressure, diabetic and venous ulcers and cavity, and some bleeding wounds. Indeed, the high 
water absorption limits wound secretions and minimizes bacterial contamination.50 The wide 
acceptance of alginates in wound healing is also related to the positive clinical advantages 
shown in various studies. For example, a randomized, controlled trial involving patients with 
full-thickness pressure ulcers reported better clinical outcomes using alginate wound dressing 
when compared to topical treatment with a dextranomer paste.51  
 Hyaluronic acid is one of the principal components of the human connective tissues and 
has become recognized as an active participant in tissue repair processes, including wound 
healing.52 It is already used in some commercially available advanced dressings such as 
Hyalofill® (Anika Therapeutics, USA), Hyalomatrix® (Anika Therapeutics, USA) and 
Hyiodine® (Contipro Pharma, Czech Republic), which have demonstrated that the application 
of exogenous hyaluronic acid on wounds can exert positive effects on the wound-healing 
process and pain management.53 Hyaluronic acid can be easily included within gauze, foams 
or creams for topical use and have a high capacity to retain water and provides a moist 
environment to protect the wounded tissue surface from dryness and promotes wound 
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healing.54  
 Collagen gives the skin its tensile strength and like hyaluronic acid, forms part of the 
natural tissue matrix, is biodegradable and plays an active part in normal physiological wound 
healing and new tissue formation, which makes it an attractive choice from a tissue 
biocompatibility and a toxicological point of view.55-57 Chitosan has ideal wound healing 
properties including hemostasis and antibacterial activity.58,59 It is reported to be able to 
stimulate formation of granulation tissue followed by angiogenesis and deposition of collagen 
fibers to further improve repair of dermal and epidermal wounds.  
 
6\QWKHWLFSRO\PHUV 
 Synthetic polymers commonly employed in wound dressings include polyvinylalcohol 
(PVA), polyethylene oxide (PEO) and polyurethane. Their hydrophilic nature imparts 
important functional wound healing characteristics such as moisture absorption capacity and 
water vapor transmission which allows maintenance of a moist wound environment whilst 
avoiding collection of excess exudate. In addition, they are generally adhesive which allows 
prolonged residence as well as being biocompatible and possessing higher mechanical strength 
than the natural ones described above. Synthetic polymer dressings can be produced using 
various techniques, such as electrospinning and hydrogel synthesis.43 Often synthetic materials 
are used in combination with natural or bioactive polymers to improve the mechanical 
properties of the final wound dressing, as in the case of electrospinned polyurethane-dextran 
nanofiber mats60 or poly(ethylene glycol)/chitosan,61 both of which are dressings with 
antibacterial activity due to the presence of ciprofloxacin hydrochloride.  
 
1.4.3.1 Hydrogels 
Hydrogels have been widely reported in the peer reviewed literature and in patents whilst 
several products are commercially available.62 A hydrogel can be described as a three-
dimensional network of hydrophilic polymers63. They can be prepared from various water 
soluble polymers with a wide range of chemical and physical properties. Hydrogels are capable 
of absorbing large volumes of water due to the presence of hydrophilic chains which allows 
them to swell extensively without changing their gelatinous nature. This property enables 
hydrogels to function as moist absorbent wound dressings64. They can be used on dry, sloughy 
or necrotic wounds but usually need a secondary dressing to hold it close against the wound 
bed65. These dressings are conventional for unusual shapes of wounds due to their jelly-like 
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nature. Hydrogels are non-particulate, non-toxic and non-adherent66. They also assist in 
providing a moist environment to dehydrated tissue to prevent them from desiccation and 
absorb exudates from wounds. Gamma radiation crosslinking was employed by Rosiak and 
co67,68 to obtain sterile hydrogels used in wound care. The materials used included natural 
polymers such as gelatin and agar and synthetic polymers such as polyvinyl pyrrolidone and 
polyvinyl alcohol. Some of the most common hydrogel dressings currently available 
commercially include Intrasite, Nu-gel, Kikgel, Aqua-gel and Aquaform. 
 
2 75$',7,21$/$1',035(*1$7(''5(66,1*6 
 Majority of dressings currently on the market, only take a passive part in the wound 
healing process. Traditional dressings include cotton, wool, natural or synthetic bandages and 
gauzes and may be used as primary or secondary dressings, or form part of a composite of 
several layers with each performing a specific function.1 These were used commonly in the 
past and though now less widely used, they are still of some benefit in certain clinic settings 
for wound treatment. Traditional wound healing agents have been largely replaced for chronic 
wounds and burns by the more recent and advanced dressings they do not provide a moist 
environment for wound healing. However, sometimes, moist  dressings showed no clinic 
advantages over treatment with traditional dressing (as for example in case of treatment of 
split-thickness skin graft donor sites109) that can be preferred due to ease of use, ready 
accessibility in most clinics and surgical centers, lower treatment costs and better patient 
acceptance.  
 Traditional dressings can provide some bacterial protection, but it is lost when the outer 
surface of the dressing becomes moistened either by wound exudate or external fluids.110 
Further, traditional dressings provide only little occlusion and allow evaporation of moisture, 
resulting in a dehydrated wound bed, and they tend to become more adherent to wounds as 
fluid production diminishes and are painful to remove.. An improvement of the properties of 
these dressings can be obtained by impregnating them with other materials or compounds to 
obtain a functional dressing. For example, paraffin (petrolatum) impregnated dressings, 
prevent sticking of the dressing to dry wound surface and are more occlusive and easier to 
remove from the skin and therefore avoids causing trauma and bleeding during dressing 
change. Gauze and bandage can also be functionalized with topical antimicrobials, which can 
prevent or reduce bacterial bioburden or reinfection especially during dressing changes. 
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Commonly used topical antiseptic agents include iodine-releasing agents (e.g. povidone iodine 
[PVP-I]), chlorine-UHOHDVLQJ VROXWLRQV HJ 'DNLQ¶V DQG VRGLXP K\SRFKORULWH VROXWLRQV
hydrogen peroxide, chlorhexidine, silver-releasing agents, and acetic acid. These compounds 
can be used to either kill or control the growth of micro-organisms in wounds111,112 and 
generally are classified as antiseptics or antibiotics and characterized by low specificity to treat 
wound infection. Antiseptics, which are disinfectants that are used on intact skin and some 
open wounds to kill or inhibit microorganisms, tend to have multiple microbial targets, a broad 
antimicrobial spectrum, and residual anti-infective activity. However, they can be harmful to 
healthy tissues and cell components essential for effective wound healing such as fibroblasts, 
keratinocytes, and possibly leukocytes.113 Antibiotics are potent antimicrobial agents or 
chemicals with high specificity, which in dilute concentrations, inhibit or kill microorganisms. 
They usually act on one specific cell target, and are relatively non-toxic, however, they are 
more susceptible to loss of activity due to the development of bacterial resistance.113 These are 
discussed in further detail under the antimicrobial dressings section below. In terms of efficacy, 
acetic acid (1%) has limited activity but has been used with great success in the management 
of wounds heavily colonized with Pseudomonas Aeruginosa.114,115 
3 '58*&217$,1,1*'(/,9(5<'5(66,1*6 
3.1 Wound drug delivery  
 Different wound types require different dressing materials possessing different 
characteristics including fluid absorption, residence time on the wound and mechanical 
strength. A relatively new approach to wound healing involves the use of polymeric wound 
dressings to deliver various pharmacological agents that can take active part in one or more 
stages of the wound healing process. The activities of these compounds together with the 
physical characteristics of the dressing can enhance the wound healing rate, whist eliminating 
some of the factors which can impair wound healing. Hydrogels, hydrocolloids, foams, films 
and wafers can be used to deliver a variety of compounds such as antimicrobials, anti-
inflammatory agents, analgesics, growth factors, proteins, and supplements directly to the 
wound site, thus increasing the efficiency of the therapy.  
$QWLPLFURELDOGUHVVLQJV 
 Many new wound dressings loaded with antimicrobial drugs were developed in the last 
20 years, taking advantage of the properties of advanced dressing to actively kill bacteria and 
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/ or fungi present in infected wounds, reduce bacteria bio-burden and prevent reinfection during 
healing, wound inspection, surgical procedures or dressing change.  
3.2.1 Wound infection 
 Infection occurs in wounds when one or more microorganisms (mainly bacteria and 
sometimes fungi) compete with the host natural immune system. Most open injuries are 
contaminated with different microbes, however, this usually has no clinical significance since 
they express no evidence of infection and heal as expected. Pathogenic bacteria, such as 
Staphylococcus aureus, Pseudomonas, aeruginosa, Streptococcus pyogenes  and some 
Proteus, Clostridium and Coliform species are the most common causes of infection and most 
frequently cited as the reason for delayed wound healing.114,116-119 Inadequate control measures 
in the management of infected wounds can lead to cellulitis and ultimately bacteremia and 
septicemia, both of which can be fatal. Wound colonization describes the presence of 
multiplying micro-organisms on the surface of a wound, but with no immune response from 
the host,120 and with no associated clinical signs and symptoms. The invasion of viable tissue 
by these microorganisms provokes a series of local and systemic host responses such as 
purulent discharge, painful spreading erythema or symptomatic cellulitis around a wound that 
can lead to soft tissue destruction.111,112 As reported by several authors, high microbial load has 
severe implications in delaying wound healing and the formation of a bacterial biofilms are 
one of the critical mediators of chronic wounds.114,121,122 It has been reported that 
approximately 75% of wounds caused by burns have a risk of infection through contamination 
by microorganisms from the sweat glands and hair follicles, gastrointestinal and upper 
respiratory tracts, and the presence Pseudomonas aeruginosa and Staphylococcus aureus 
significantly reduced skin graft healing.114,123-125 Chronic wounds are prone to infection due to 
the formation of high microbial bioburden and inability of leukocytes to deal with impaired 
migration, phagocytosis and intracellular killing of microorganisms.126 Local tissue necrosis, 
hypoxia, ischemia and some immune deficiencies such as the one caused by human 
immunodeficiency virus (HIV) or chemotherapy are factors that promote wound infection.114  
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$QWLELRWLFGUXJV 
 The use of antibiotic drugs for local wound application is gradually becoming popular, 
at least in the scientific literature, due to many factors, the most common being the lower 
amounts required when applied directly at the wound sites compared to systemic administration 
via injections or the gastrointestinal route. Different classes of antibiotics have been used in 
wound dressings for delivery to wound sites, and a selection of these are summarized in table 
4. Treatment of wound infection requires a decrease in exogenous microbial bioburden which 
can be achieved using various approaches including topical and systemic broad-spectrum 
antimicrobial agents, debridement of devitalized tissue, appropriate dressing, maximization of 
immune resistance and provision of adequate nutrition.114,128,129 Combinations of antibiotics 
can be used to cover multidrug resistant microorganisms, however, clinical data supporting this 
strategy are limited.127 
 
Table 4. Different antibiotics and the type of dressings used to deliver them to infected wounds. 
Delivery system Drug Author / Reference 
Chitosan films Minocycline Aoyagi et al.138  
Chitosan sponges Vancomycin Stinner et al.139  
Polyox composite film  Streptomycin Pawar et al.82  
Polyox/carrageenan composite 
film Streptomycin Boateng et al.
80
  
Polyox/carrageenan and 
polyox/sodium alginate wafers Streptomycin Pawar et al.
81
 
Wafers  Neomycin Labovitiadi et al.140  
Polysaccharide wafers  Chlorhexidine digluconate Labovitiadi et al.
141,142
  
Electrospun polyurethane-
dextran nanofiber mats Ciprofloxacin Unnithan et al.
60
  
Poly(ethylene glycol)/chitosan 
scaffold Ciprofloxacin Sinha et al.
61
  
 
However, the persistent emergence of antibiotic-resistant strains of pathogens, together with 
the reduced rate of new antibiotics coming through the drug discovery pipeline has resulted in 
the need for alternative treatments to manage wound infections more effectively. To overcome 
this problem, novel dressings containing non-antibiotic compounds (e.g. silver and plants) are 
continually developed and their use can enhance the antimicrobial activities of dressings, 
limiting the occurrence of antimicrobial resistance.130-137  
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6LOYHU 
 Silver, and the newer silver nanoparticles (AgNPs) have been recognized as optimal 
candidates for overcoming pathologies previously treated with conventional antibiotics, 
because of their strong and broad-spectrum antimicrobial characteristics.  
 Various mechanisms have been proposed for sLOYHU¶V DQWLEDFWHULDO DFWLRQ. The first 
proposed mechanism involves bacterial cell membrane enzyme protein deactivation by binding 
to thiol groups. These proteins are known to take part in membrane energy production and ion 
transport.143 Davis and Etris144 reported that silver is involved in catalytic oxidation reactions 
resulting in disulfide bond formation by catalyzing reactions between oxygen present in the 
cell and hydrogen from thiol groups, ultimately inhibiting cell function due to changes in 
protein structure. Other authors have reported the binding of silver to the 30S ribosomal subunit 
thereby preventing protein translation.145 Another mechanism reported involves the entry of 
SRVLWLYHO\FKDUJHGVLOYHU LRQV LQWR WKHFHOODQGGHQDWXULQJ'1$E\ µORFNLQJ¶ LWVHOIEHWZHHQ
purine and pyrimidine base pairs143 though this has not been proved conclusively. For silver to 
exhibit antibacterial activity it needs to be in the ionized form and therefore unionized silver 
metal is non-active and only becomes active in the presence of moisture (exudate in the case 
of wounds).146,147  
 New wound dressings have been developed that release silver to help prevent wound 
infections caused by both Gram-positive and Gram-negative bacteria both in vitro and in 
vivo.148 In the past, the use of silver has been severely limited by the toxicity of its ions to 
humans, however, the development of nanotechnology has facilitated the production of nano-
structured silver particles with a high surface area (and therefore a higher area- to-volume ratio) 
that demonstrates greater efficacy against bacteria and more importantly, less toxicity to 
humans.131  
1RYHOFRPSRVLWHVFDIIROGGUHVVLQJFRPSULVLQJȕ-chitin and AgNPs for wound healing 
showed bactericidal activity against Escherichia coli and Staphylococcus aureus in addition to 
good blood-clotting ability due to chitin.149 In a related study, Bishweshwar and co-workers 
reported on nylon nanofibers incorporating AgNPs by an electrospinning method for wound 
healing.150 Their results showed that the composite system exhibited antibacterial activity 
against Gram-negative Escherichia coli and Gram-positive Staphylococcus aureus. Silver 
loaded dressings have also been reported as effective against non-bacterial targets, including 
fungi.151In a recent study, silver-containing activated carbon fibers compared with commercial 
silver dressings were investigated to determine the effects of different silver concentrations on 
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the dressing efficacies.152 that the ³YDULRXVVLOYHU-containing activated carbon fibers exhibited 
good antibacterial effects and biocompatibility in terms of cell viability and that silver 
concentration showed a minor influence on celOJURZWK´7KH authors concluded that silver-
containing activated carbon fiber and other commercial silver dressings aided wound healing 
by promoting granulation and collagen deposition. Chitosan and polyvinyl pyrolidone based 
film dressing containing silver oxide has been functionally evaluated for potential wound 
healing properties, compared to cotton, pure chitosan and other chitosan based dressing.153 The 
results showed better performance of the composite chitosan-PVP-silver oxide dressing 
compared to the other materials.  
Commercially, there are many dressings which are just upgrades of existing polymer 
based moist wound dressings, loaded with silver either in pure form, as salts or as nanoparticles 
for treating and / or preventing infection in various wound types. The different silver loaded 
dressings currently available on the market are summarized in table 5 below. Most of these 
have been reported in the peer reviewed scientific literature and shown in most cases to have 
antibacterial activity both in vitro154,155 135,136 and in vivo.156,157  
Table 5. Commercially available wound care products containing silver.158  
FORMULATION PRODUCT NAME MANUFACTURER SILVER FORM  
Fibrous / cloths, 
others 
Silverseal Derma Sciences Silver oxide 
Tegaderm Ag Mesh 
Dressing with Silver 
3M Silver sulfate 
Urgotul SSD Laboratoies Urgo Silver sulfadiazine 
Vliwaktiv Ag, Absorbent 
Activated Charcoal 
Lohmann and Rauscher Silver  
Vliwaktiv Ag, Activated 
Charcoal Rope with Silver  
Lohmann and Rauscher Silver  
Films / meshes Acticoat 7 Smith and Nephew Elemental silver 
Arglaes film Medline Silver  
Restore Contact Layer with 
Silver 
Hollister Wound Care LLC Silver chloride 
Foams Acticoat Moisture Control Smith and Nephew Elemental silver 
Allevyn Ag  Smith and Nephew Silver sulfadiazine 
Biatain Ag Coloplast Silver 
Mepilex Ag Molnlycke Silver 
Optifoam Ag Adhesive Medline Ionic silver 
Optifoam Ag Non-adhesive Medline Ionic silver 
PolyMem Silver Island  Ferris Mfg. Corp. Elemental silver 
PolyWic Silver  Ferris Mfg. Corp. Elemental silver 
Restore non-adherent foam 
with silver 
Hollister Wound Care LLC Silver 
Silverlon Negative Pressure  Argentum Medical, LLC Ionic silver 
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SilverSite Centurion Silver alginate 
UrgoCell Silver/Cellosorb 
Ag 
Urgo Medical Silver salts 
V.A.C GranuFoam Silver KCI Silver 
Gauze Urgotul SSD/S.Ag  Urgo Medical Silver sulfadiazine 
Hydrocolloid Contreet Hydrocolloid Coloplast Silver  
SILVERSEAL Hydrocolloid  DermaSciences Silver 
SureSkin EuroMed Silver zeolite 
Hydrofiber Aquacel Ag ConvaTec Ionic silver 
Hydrogel Elta Silvergel Elta Silver 
ExcelGinate Ag MPM Silver  
Gentell Ag Hydrogel Wound 
Dressing 
Gentell Silver sulfadiazine 
Silvasorb Gel Medline Ionic silver 
SilverMed Antimicrobial 
Silver 
MPM Silver 
SILVERSEAL DermaSciences Silver oxide 
Silver-Sept Antimicrobial 
Gel 
Anacapa Tech Inc Silver salt 
Powder Arglaes Powder Medline Silver  
Wash SilverMed Antimicrobial 
Wound Cleanser 
MPM Silver microparticles 
 
$QWLPLFURELDOSHSWLGHVDQGEDFWHULRO\WLFHQ]\PHV 
Infections caused by multi-drug resistant organisms, including methicillin-resistant 
Staphylococcus aureus (MRSA), vancomycin-resistant Staphylococcus aureus (VRSA), 
extended spectrum beta-lactamase (ESBL), vancomycin-resistant Enterococcus (VRE) and 
multidrug-resistant Acinetobacter baumannii (MRAB) can lead to increased patient morbidity 
and mortality and increase of the cost of treatment due to prolonged hospitalization. 
Antimicrobial peptides (AMPs) are recognized as promising candidates to overcome infections 
caused by resistant bacteria. These therapeutic agents are widely synthesized in nature by 
microorganisms, plants and animals (both invertebrates and vertebrates) as components of their 
natural defences against invading pathogens. AMPs are active against a broad spectrum of 
microorganisms, including multidrug-resistant strains such as MRSA, VRSA, ESBL, VRE and 
multidrug-resistant Acinetobacter baumannii due to the fact that they have a low propensity 
for developing microbial resistance making them very efficient at treating infection159.140 This 
activity is attributed to a rapid mechanism of action and the ability to discriminate between 
host and microbial cells (cell selectivity) making them promising candidates for clinical 
applications and potential alternatives to conventional antibiotics. More than 2,000 
antimicrobial AMPs have been reported with differences in their sequence and structure, and 
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they all are generally low molecular weight (10±50 amino acids) peptides and have at least two 
positive charges.160  
AMPs are widely used to functionalize biomaterial surfaces which impart to it anti-
biofilm properties and their immobilization within wound dressings is just one of the 
applications in the biomedical field.161 Chemically and physically cross-linked natural and 
synthetic hydrogels are probably the most versatile platforms for the delivery of drugs and 
peptides to mitigate biofilm formation. In particular, when hydrogels are used to 
simultaneously co-deliver antimicrobial polymers/peptides and conventional antimicrobial 
agents, a strong synergistic effect can be achieved.162 Biodegradable antimicrobial polymers or 
peptide-loaded gels are more attractive than gels loaded with antibiotics or metal (e.g. silver) 
nanoparticles since bacteria easily develop resistance to antibiotics, and the non-degradability 
of metal nanoparticles can result in toxicity. Good results were also obtained when AMPs were 
included in freeze-dried wafers, polyelectrolyte multilayers or cotton gauzes.163,164  
The use of bacteriolytic enzymes can be another promising strategy for the treatment 
and prevention of drug resistant organisms and biofilm establishment. The biopolymers 
involved in cell attachment are the main target of such enzymes, leading to an inhibition of 
biofilm formation or promoting detachment of established biofilms. Several enzymes have 
been shown to exhibit this anti-biofilm activity and are currently extensively studied for 
preventing bacterial colonization on surfaces if incorporated into anti-biofilm coatings.161 
Recently, Miao et al. proposed the use of these molecules to produce a functional wound 
dressing with antimicrobial activity against a drug resistant bacterial strain.165 Lysostaphin, a 
cell lytic endopeptidase derived from bacteriophages, was immobilized onto biocompatible 
polymeric fibers generated by electrospinning to obtain an anti-infective bandage. The 
resulting dressing was tested in an in vitro skin model, and showed good activity against 
Staphylococcus aureus and a low toxicity toward keratinocytes, suggesting a possible 
application of these materials as antimicrobial wound dressings. Other hydrolytic enzymes 
derived from bacteriophages have been proposed as promising and potent antibacterial 
therapeutics even against MRSA and VRSA strains, and for this reason they can become an 
interesting future therapeutic tool as first line antibiotics in the battle against resistant bacteria 
strains.166  
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3RO\KH[DPHWK\OHQHELJXDQLGHK\GURFKORULGH3+0% 
PHMB is a low molecular weight polymer with structure (figure 3) related to 
chlorhexidine. It is an antimicrobial agent with broad spectrum activity against several Gram-
positive and Gram-negative bacteria, fungi and yeast and reported to be particularly active 
against the difficult to control Pseudomonas species. Due to its water solubility, it is used in 
water-based products, which are most susceptible to microbial growth. As a preservative, 
PHMB is used in cosmetics, personal care products, fabric softeners, contact lens solutions and 
hand washes. Moreover, PHMB has also been used to prevent microbial contamination in 
wound irrigation and sterile dressings and has been reported for use in reducing bloodstream 
infection caused by catheter use.167 In a study comparing electrospinned polylactide (PLA) 
nanofibers loaded with either PHMB or chlorhexidine, it was shown that the nanofibers became 
smoother and their diameter smaller with increasing amount of PHMB with a resultant increase 
in surface roughness and hydrophobicity of the scaffold.137 The PHMB-loaded PLA scaffolds 
showed antibacterial properties by inhibiting adhesion and bacterial growth, and at the same 
time exhibited biocompatible characteristics that allowed cell adhesion and proliferation of 
fibroblasts and epithelial cells in vitro.137 In a randomized clinical trial, comparing the 
effectiveness of bio-cellulose dressing containing PHMB with silver sulfadiazine cream, in 
partial thickness burns, the former showed faster and better reduction in pain compared to the 
silver sulfadiazine cream. This suggests that PHMB reduced the duration of inflammation by 
controlling infection..168 Dilamian et al.169 prepared composite electrospinned membranes 
using chitosan and polyethylene oxide incorporating PHMB to impart antimicrobial properties 
for use as a medical biomaterial. The effect of PHMB on the electrospinnability and 
antimicrobial properties of chitosan/PEO nanofibers were studied together with viscosity of the 
solutions and nanofiber morphology. The results showed that PHMB in chitosan/PEO solutions 
resulted in decreased zero-shear rate viscosity up to 20%, whilst increasing PHMB from 0.5 
mM to 1 mM led to formation of thinner fibers. The drug loaded fibers showed activity against 
Escherichia coli and Staphylococcus aureus with a burst release of PHMB from the materials 
in the first hour.169  
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Figure 3 Chemical structure of PHMB 
$QWLLQIODPPDWRU\DQGDQDOJHVLFGUHVVLQJV 
 Wound healing begins with an acute inflammatory phase within a few hours after injury 
with release of exudate rich in proteins. This causes vasodilation through the release of 
histamine and serotonin, which allows phagocytes to enter the wound and engulf dead cells. 
As a result of this inflammatory phase a wound clot is formed, to stop bleeding, and 
givestrength and support to the injured tissue. However, this inflammatory phase is also 
characterized by swelling and pain, which can be severe in certain wound types. In chronic 
wounds, the wound is stuck in a continuous cycle of inflammation and patients can be in 
constant pain, which can be very debilitating. Pain also occurs either due to repeated tissue 
insults caused by physical trauma, but most common wound pain is probably due to dressing 
change, especially in the case of dry wounds, debriding, and wound cleansing. In addition, 
wound infection can contribute to wound pain by triggering a continuous inflammatory 
response. The response against the infecting microorganisms causes the release of 
inflammatory mediators and stimulates the production of enzymes and free radicals, which can 
cause tissue damage.170 Furthermore, the pain-related stress reduces the immune response to 
infection and stimulates pro-inflammatory cytokine production in wounds.171 For these reasons 
the treatment of pain and infection should be prioritized on an equal basis.  
 Wound pain can be classified into two types: nociceptive and neuropathic pain. 
Nociceptive pain is an appropriate physiological response to a painful stimulus, and occurs as 
a result of tissue damage. This type of pain is usually time limited, but when the wounds are 
slow to heal, the prolonged inflammatory response may cause heightened sensitivity in both 
the wound (primary hyperalgesia) and in the surrounding skin (secondary hyperalgesia).171 
Neuropathic pain is an inappropriate response caused by a primary lesion or dysfunction in the 
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nervous system. Nerve damage is the commonest cause of the primary lesion, which may be 
due to trauma, infection, metabolic disorder or cancer. Neuropathic pain is a major factor in 
the development of chronic pain.172 Reduction of pain is the highest treatment priority from the 
SDWLHQW¶V SHUVSHFWLYH HVSHFLDOO\ LQ the case of a chronic wound. An appropriate wound 
PDQDJHPHQWFDQVLJQLILFDQWO\LPSURYHDSDWLHQW¶VTXDOLW\RIOLIHDQGPD\LQGLUHFWO\SURPRWH
healing by improving appetite and sleep.173 In skin transplants to help wound regeneration, the 
wound created is extremely painful since the layer of skin harvested touches the painful nerve 
endings and therefore requires pain management at the secondary wound site. 
   
Topical treatment using pharmacological agents is an effective and safe approach to 
manage wound pain. Medicated dressings can perform the two essential functions (i) the 
treatment of the cause (e.g. wound infection) and (ii) the management of the actual wound pain. 
The treatment of wound infection, by reducing bacterial load and thereby reducing the 
inflammatory stimulus to the nervous system, should result in a reduction in pain. 
Antimicrobial drugs, however, may take some days to have a significant effect on pain. 
Therefore, to obtain rapid pain relief, dressings loaded with drugs, such as local anesthetics 
(e.g. lidocaine), or NSAIDs can be very useful to reduce wound pain during wear time and at 
dressing change. In particular, ibuprofen has excellent local effects on superficial wounds, 
without detectable systemic levels174  and provided clinically relevant pain relief for patients 
with exuding, painful venous ulcers.175-178 In a multi-center randomized controlled trial, 
Arapoglou and co-workers examined the analgesic effect (over 5 days) of foam dressings 
loaded with ibuprofen (112.5 mg) compared to local best practice wound management in 
various wound types (arterial, venous and mixed arterial-venous ulcers, vasculitis an traumatic 
ulcers).175 They showed that the ibuprofen releasing foam dressing produced significantly 
higher analgesic effect than the local best practice group based on patient scores. They 
concluded that local pain relief by ibuprofen is possible in the most common painful exuding, 
chronic and acute wounds and therefore a safer alternative to systemic drug administration.175 
Romanelli et al. showed that the commercial ibuprofen containing foam dressing (Biatain Ibu, 
Coloplast, Denmark) provided better pain relief for painful exuding wounds compared to 
patients treated with local best practice wound management.178 
 Another option to induce efficient analgesia in patients with severe skin wounds is the 
topical application of opioids. Opioid receptors are up regulated during inflammation and in 
addition to its analgesic functions, they can also directly modulate the inflammatory process 
and wound healing.179,180 Topical opioid treatment can be used to achieve local analgesia and 
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increase wound healing, reducing the severe adverse effects of systemic administration. 
Furthermore, wound dressings can be properly engineered to ensure a slow release, increasing 
the safety and extending the interval between regular dressing changes.181  
 
4 $'9$1&(''5(66,1*6&217$,1,1*
%,2/2*,&$/$*(176 
4.1 *URZWKIDFWRUV 
 The use of growth factors to promote wound healing has always been considered one 
of the possible therapeutic approaches to overcome the problem of difficult to heal (chronic) 
wounds. Growth factors (GFs) are a class of biomacromolecules locally secreted by the 
extracellular matrix (ECM), capable of regulating biological processes by transferring signals 
between cells and their local environment, regulating proliferation, migration and 
differentiation of cells.182,183 Interactions between the ECM, GFs, and cells are fundamental to 
all phases of wound healing and abnormalities in those interactions usually lead to chronic 
wounds.184 In an exhaustive review, Barrientos et al.185 summarized the action and the 
therapeutic effects of various GFs in the clinical management of non-healing wounds. Four 
GFs have shown the greatest potential for wound healing in randomized controlled trials: 
granulocyte-macrophage colony-stimulating factor (GM-CSF), platelet derived growth factor 
(PDGF), basic fibroblast growth factor (bFGF) and vascular endothelial growth factor 
(VEGF).186 The local application of the GFs on the wound site is essential to exert a therapeutic 
action on wounds, but the need for continuous local injection makes this formulation difficult 
to use in clinical practice. The formulation of GFs in a topical delivery system (cream, gel or 
ointment) directly administered to the wound surface could facilitate their therapeutic 
application in the clinical management of non-healing wounds. However, to date, only 
REGRANEX® Gel (Becaplermin 0.01%, Smith & Nephew, UK) has been approved by the 
FDA for the treatment of diabetic foot ulcers.187,188 Despite the ability of Becaplermin to 
accelerate wound closure and significantly reduce amputations,189-192 its use is expensive, 
requires frequent dressing changes and is associated with an increased risk of cancer.188  
 Polymeric wound dressings were successfully developed for incorporation of free GFs 
using biocompatible biomaterials such as gelatin,193,194, dexran,195, collagen196  or chitosan.197. 
Micro and nano encapsulation are often necessary to protect GFs during the formulation and 
production phases and to achieve a long-term exposure, a characteristic required for the 
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delivery of GFs to chronic wounds. Furthermore, as reported by Ulubayram et al.194, 
incorporating GFs into a wound dressing either in free form or loaded within microspheres, (to 
provide sustained release) have shown greater effects in wound healingthan only free GFs. 
Electrospinned nanofibers is another very popular approach to develop novel multifunctional 
platforms by integrating controlled release strategies within scaffolding materials, which are 
able to control and regulate the wound healing process.198 Different fabrication techniques have 
been used for the development of GFs±loaded electrospinned fibers. GFs can be incorporated 
into the nanofibers199 or conjugated onto the fibers surface200 and different release 
characteristics are obtained, depending on the loading method. An interesting hybrid approach 
was proposed by Kulkarni et al. which used a layer-by-layer assembly technique, to obtain a 
dressing able to preserve the bioactivity of encapsulated EGF whilst allowing the tuning of 
EGF release for an extended period, depending upon the number of layers deposited onto the 
surface.201  
 Wound healing is one of the most complex mechanisms in the human body where 
multiple cellular pathways are simultaneously activated by different molecules. For this reason, 
the delivery of a single GF might be insufficient and a combined action of different GFs was 
shown to improve the reparative processes in the wounded skin of diabetic mice better than 
single-agent treatment.202 Furthermore, the local concentration and the spatio-temporal 
gradients can be crucial for a successful treatment and combining different preparation 
techniques provides the possibility of simulating the natural conditions involved in the wound 
healing process. Using a combination of encapsulated and free GFs, it is possible to engineer 
a multiple release system with a controlled, sequential release of GFs mimicking the 
physiological action sequence and providing the most effective outcome. Multiple GFs 
including bFGF, EGF, VEGF and PDGF were encapsulated in collagen and hyaluronic acid 
based electrospinned nanofibers loaded with gelatin nano-capsules by Lai et al. for sequential 
release of the GFs on the wound site196 GFs encapsulated either in nanofibers or in 
nanoparticles are released over 1 month by gradual degradation of nanofibers/nanoparticles 
simulating the temporal release of regulatory factors in the normal wound healing process. The 
initial delivery of bFGF and EGF bio-mimics the early stage of the wound healing process, 
whereas slow controlled release of VEGF and PDGF-BB imitates the late stage of skin 
reconstruction promoting re-epithelialization, dermal reconstruction and formation of mature 
vasculature as confirmed by in vivo studies on streptozotocin-induced diabetic rats.196 
 Platelets can constitute a natural potential source of multiple GFs and proteins involved 
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in tissue regeneration. For this reason topical treatments with platelet derivatives have 
increasingly been described as capable of accelerating wound healing and to aid in tissue 
repair.203 Platelet lysate (PL) is a hemo-derivative obtained through platelet destruction by 
freeze-thawing and was shown to have activities of different cell types involved in wound 
healing.204 The possibilities to use allogeneic PL, which minimizes individual variability, 
represents an advantage compared to patient derivatives such as platelet-rich plasma (PRP) or 
platelet-rich fibrin (PRF). Different controlled-release systems have been developed to provide 
sustained delivery of PL to the wound, including sponge-like dressings,205 mucoadhesive 
gels206 and eyedrops.207 Recently a powdered alginate formulation was proposed for the 
combined delivery of PL and vancomycin hydrochloride in chronic skin ulcers.208 The alginate 
particles released the active drugs and also absorbed wound exudates to form a gel and at the 
same time enhance fibroblast proliferation.208 
4.2 1XFOHLFDFLGV 
 The local delivery of GFs presents some challenges and there has been limited   success 
of clinical trials.  The combined effects of physical inhibition and biological degradation cause 
significant loss of drug activity which minimizes their therapeutic efficacy. The introduction 
and expression of exogenous DNA into a host cell to achieve a permanent insertion (known as 
gene therapy) or transient transformation (gene medicine) has great potential in the treatment 
of wounds, stimulating the cells themselves to produce the GFs directly onto the wound site.209 
Such an approach could avoid the degradation of GFs on the wound site and achieve a 
temporary expression of these factors until wound closure. One of the first attempts to use a 
plasmid DNA coding for interleukin 8 (IL-8) genes in wound healing was by Hengge et al. by 
injecting naked genes into the skin which resulted in a significant recruitment of dermal 
neutrophils.210 However, naked DNA constructs injected into the skin has been proven to have 
a low transfection efficiency due to their fragility in the extracellular environment, large size 
and electrical charge. The transfection efficiency can be enhanced using a gene-activated 
matrix (GAM) that, allows better control over the duration of transgene expression and 
promotes new tissue formation in a more effective way. A controlled release from a matrix can 
maintain the right level of the vector over time, providing repeated opportunities for 
transfection/transduction and extending transgene expression. For this reason, the design 
parameters of gene-loaded scaffolds (e.g. material, architecture, vector incorporation, 
biochemical cue presentation) are very important and directly affect the transgene expression 
and tissue repair.211 Biodegradable carriers loaded with adenoviral vectors have been 
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investigated for gene transfer in different animal wound healing models showing an increased 
granulation tissue formation, vascularization and re-epithelialization compared to controls 
treated with carriers alone or carriers containing a reporter gene vector. 212-214 However, the 
limited loading capacity, the high costs of production and the safety risk restrict their 
application range. Synthetic DNA delivery systems, known as non-viral vectors, have the 
advantage to deliver genes to target cells without the potential for recombination with wild type 
viruses and possible cellular damage due to repeated exposure to the viral vectors.215 Typically, 
these non-viral vectors are complexes of naked plasmid DNA (pDNA) with cationic polymers 
(polyplex), lipid (lipoplex) or inorganic particles. These synthetic constructs have a lower risk 
of toxicity and offer the possibility of using a wider range of DNAs with different sizes, but at 
the expense of lower transfection efficiency compared to viral vectors. The transfection rate 
and the consequent success of the therapy, depends  on the degradation rate of biomaterials and 
the cellular infiltration into the scaffolds. The control of these two parameters allows a 
modulation of the therapeutic action over a long period of time, making this system very 
attractive for wound dressing application. Hydrogels containing pDNA coding for TGF-
beta1216 and VEGF217 have already been shown to promote wound healing in mouse wound 
models. Electrospinned nanofibers can be easily engineered to obtain scaffolds for delivery of 
nucleic acids due to their high surface area, high porosity and interconnected pores beneficial 
for cell adhesion/proliferation and oxygen/nutrient transfer.198. The blending of DNA with an 
electrospinning solution did not give satisfactory results due to improper encapsulation and 
transfection efficiency132 but the development of other techniques, such as the incorporation of 
DNA-loaded particles into nanofibers, core±shell nanofibers, or surface modification, helped 
to overcome the low transfection efficiency of naked DNA-loaded nanofibers.198 y Saraf et al., 
formulated a fiber mesh scaffold containing a non-viral gene delivery vector 
polyethyleneimine-hyaluronic acid complex (r-PEI-HA) and pDNA within the sheath and core 
of the fiber, respectively.218 They showed that the release rate and the transfection efficiency 
could be tuned by changing parameters such as concentration of pDNA and molecular weight 
of the core polymer.  
 Small interfering RNAs (siRNA) are small pieces of double-stranded mRNA that can 
inhibit gene expression and prevent the production of specific proteins.219 The use of siRNA in 
wound healing could provide a gene-specific silencing of inflammatory or other specific 
proteins directly involved in chronic wounds. However, for an effective siRNA wound therapy, 
it is necessary to protect and deliver the nucleic acid directly into the cytoplasm, a process 
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complicated by the very short half-life in vivo and by the difficult cellular internalization.219 
Research in this field is very attractive and many biomaterials and nanoparticles (NPs) are 
constantly developed and optimized to create efficient delivery systems for siRNA.220 
Biodegradable scaffold injected or implanted directly at the wound site have already been 
investigated and demonstrated the ability to achieve a high level of gene silencing efficiency 
and tunability in vivo.221 However, despite the enormous potential of these technologies in 
wound healing, only few attempts222,223 have been made to develop dressings or medical 
implants for localized and sustained siRNA delivery to the wound. 
4.3 6WHPFHOOV 
 In recent years, there has been increasing evidence showing that the paracrine effect of 
stem cells can play an important role in wound healing, in particular regulating the levels of 
cytokines and GFs around the wound site.224-226 Compared to many differentiated cell 
phenotypes, stem cells are potentially permanent residents of the wound site and naturally 
modulate the healing response in acute and chronic wounds, synthesizing and delivering 
multiple GFs. The use of biomaterial scaffolds loaded with stem cells can provide a local 
delivery of GFs, and at the same time, strengthen the action of the stem cells which creates a 
favorable environment to promote cell adhesion, proliferation, migration and differentiation. 
Different cell types and methods can be used in the stem cell therapy of wound healing and 
Branski et al. have provided a detailed outline of these technologies.227 Bone marrow-derived 
stem cells (BMSCs) are probably the most studied marrow-derived stem cells (MSCs) and 
several clinical studies have demonstrated their usefulness in wound healing.228,229 However, 
bone narrow harvesting is an invasive, and painful procedure and some pathologic conditions 
(e.g. severe burn trauma, sepsis, silver sulfadiazine toxicity or old age) can reduce the BMSCs 
availability.227  
Adipose-derived stem cells (ADSCs) are considered an interesting alternative to BMSCs 
for wound healing application because they express a similar array of cytokines and GFs and 
can be easily isolated from sections of whole fat (biopsy) or lipo-aspirate, which means a less 
aggressive and painful harvesting procedure. The biggest challenge in the use of MSCs is to 
keep the cells in contact with the wound bed and keep them viable in the hostile wound 
microenvironment. In situ forming injectable hydrogel dressings have been successfully 
applied for the delivery of large volumes of cells or biomolecules as they allow the retention 
of the cells at the injection site, therefore increasing efficiency. Furthermore, the relative ease 
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of loading living cells into those systems and the conformability to complex tissue or implant 
shapes make hydrogels a very popular scaffold for cell encapsulation.230 BMSCs231 and 
ADSCs232 loaded thermo-responsive hydrogels have already been tested in wound models and 
showed potential as a bioactive wound dressing. A new interesting application of ADSCs is as 
filler in biodegradable sutures to provide a local pro-regenerative effect at the injured site. The 
simultaneous release of key molecules involved in the different phases of wound healing in 
association with the mechanical wound fixation, represents a promising tool to promote wound 
healing. 
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5.1 1DWXUDOO\RFFXUULQJSODQWFRPSRXQGV 
The development of new wound management products based on traditional or 
alternative medicine has become very popular in recent years. Before the advent of modern 
medicine, people of all continents used medicines from natural sources and nowadays the 
percepWLRQWRZDUGVWUDGLWLRQDOPHGLFLQHKDVDOVRFKDQJHG1DWXUDOSURGXFWVLQFOXGLQJWKHȕ-
glucans, aloe, honey, cocoa, essential oils and oak bark extracts are already used in wound 
healing.233 However, the lack of standard methods to evaluate their composition has made it 
more difficult to determine the true efficacy of these products for wound healing.  
 
5.1.1 Aloe vera 
Aloe vera (Aloe barbadensis) preparations have been used for centuries to treat wounds 
and burns and LW¶Vwound healing properties have always attracted the interest of the scientific 
community. Aloe vera gel is an extremely complicated mixture of natural products, but the 
biological activity is principally attributed to polysaccharides and glycoproteins (e.g. lectins) 
present in the leaf pulp.234 Acemannan, the main polysaccharide present in aloe vera gel, seems 
to play an important role in the wound healing process by inhibiting bacterial growth and 
stimulating macrophage activity.235 Furthermore, the anti-septic and antimicrobial activity are 
also related to the presence of natural antiseptic agents such as lupeol, salicyclic acid, urea 
nitrogen, cinnamonic acid, phenols and sulfur, which have inhibitory activity against fungi, 
bacteria and viruses.236 Several authors have already proposed the use of aloe vera as alternative 
to synthetic drugs to develop active wound dressing materials useful for wound healing 
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applications.237-239  
 
5.1.2 Other plant extracts 
Table 6 summarizes the use of other herbal medicines useful in wound care. Plant 
extracts from Chamomilla recutita,240 Hamamelis virginiana,241 Polisiphonia lanosa 
seaweed,242 Acacia arabica and Moringa oleifera,243  are already being employed in the 
development of advanced wound dressings. Recently, a collagen sponge containing an extract 
of Macrotyloma uniflorum, generally utilized as cattle feed, was developed by Muthukumar 
and coworkers.244 The plant extract imparts antimicrobial activities to the sponge and at the 
same time, increased the tensile strength and the stability against collagenase enzyme.  
Table 6. Extracts from different plants useful in wound healing. Adapted from Dorai et al.244,245  
Herbal medicine 
Properties 
Aspilia Africana Hemostatic properties on wounds, inhibits the growth 
of microbial organism, accelerates wound healing, 
treatment of rheumatic pain, bee and scorpions stings, 
remove corneal opacity and foreign bodies from the 
eyes 
Bridelia ferrugunea, Parkia 
biglobosa Jacq 
Increased the proliferation of dermal fibroblast 
Elaeis Guineensis leaf extract Improve tissue regeneration 
Cedrus libani, Abies cilicica 
subsp cilicica 
Improved wound healing and anti-inflammatories 
properties 
Carapa Guineensis leaves Increased rate of wound contraction, skin breaking 
straight and hydroxyproline content 
Combination of Yasha 
Bhasma, shoea robusta and 
flax seed oil 
Increased wound contraction, higher collagen content 
and better skin breaking straight  
Hippophae rhamniodes L Improve wound healing 
Carica papaya latex Increased wound contraction and epithelialization rate 
Methanol extract of 
Heliotropium indicum Linn. 
leaves 
Improve wound healing 
Rafflesia hasselti, buds and 
flower extract 
Improve wound healing rate and wound contraction 
Melaleuca alternifolia Antimicrobial, antiseptic, antiviral, antifungal and anti-
inflammatory properties 
 
Essential oils are the volatile products of secondary metabolism of plants and can be 
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obtained from plant flowers, seeds, leaves, fruits and roots most commonly via distillation, 
expression or solvent extraction. Approximately 3,000 essential oils are known, of which 
around 300 are commercially important.136 Some of these, such as thyme oil, oregano, bay, 
lavender, peppermint, cinnamon, tea tree, rosemary, eucalyptus and lemongrass  have been 
found to exhibit antimicrobial properties, but only lemongrass, oregano and bay essential oil 
showed antimicrobial activity at concentrations <<2% (v/v).246 Liakos et al.247 tested the 
antimicrobial and antifungal properties of nine different essential oils at three different 
concentrations incorporated in a sodium alginate-based film. The loaded films showed the 
capacity of inhibiting bacterial and fungal growth depending on the essential oil type and 
concentration and can be suitable to use as novel antimicrobial wound dressing. Several other 
studies have been conducted on the antimicrobial activity of essential oils in wound dressing 
systems. Thyme oil was successfully incorporated into chitosan films to obtain antibacterial 
and permeable films for wound healing applications.249 Thyme oil showed good antimicrobial 
effects on both Gram-negative and Gram-positive microorganisms and its efficacy as safe and 
effective source of natural antioxidant and antimicrobial agents was confirmed also by their 
incorporation into gelatin films250 and N-carboxybutylchitosan /agarose foam using 
supercritical carbon dioxide.251 Eugenol and limonene were doped in nanofluid-based 
magnetite and used to fabricate modified wound dressings with antimicrobial properties.252 
Garcinia mangostana extracts were incorporated into electrospinned chitosan based nanofiber 
mats that showed the ability to inhibit the growth of Staphylococcus aureus and Escherichia 
coli.253 However, essential oils, due to their hydrophobicity, tend to have a poor dispersion and 
eventual phase separation can occur either in solution or in the final dried film. To avoid these 
phenomena and improve the dispersion and the stability of the essential oils, the use of a 
surfactants is often required. A different approach was used by Catanzano et al.248 who 
proposed a microemulsion as carrier to obtain a homogeneous distribution of tea tree oil in an 
alginate hydrogel. 
5.2 +RQH\ 
 in which nectar is collected and stored in beehives. Over centuries, honey, produced by 
the pollination bioactivity of industrious honeybees (Apis mellifera), has been valued for its 
biomedical activity in treating various types of wounds including burns, diabetic ulcers, 
pressure ulcers and leg ulcers.254 Different ancient Sumerian and Greek manuscripts mentioned 
the use of honey as a drug against wounds such as ulcers.255Even as far back as World War I, 
Russian soldiers used honey to prevent wound infection as well as to accelerate healing of their 
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wounds. The Germans also used honey in combination with cod liver oil to treat ulcers, burns, 
fistulas and boils.256 A broad spectrum of wounds are reported to be responsive to honey, 
including scratches, boils, amputation, leg ulcers, burns, chill blains, burst abdominal wound, 
cracked nipples, fistulas, diabetic, malignant, leprosy, traumatic, cervical, varicose and sickle 
cell ulcers, septic wounds, surgical wound or wounds of abdominal wall and perineum257.238 
The pharmacological activities of honey258,259 relevant for wound healing include, 
antimicrobial, deodorizing, debriding, osmotic, anti-inflammatory and antioxidant actions 
which are known to enhance the rate of wound healing.260 Various studies have demonstrated 
the antimicrobial effectiveness of honey in killing challenging wound-infecting bacteria261 with 
significant increase in randomized clinical trials using honey to treat wounds.259 In its natural 
state, honey contains major and minor ingredients which account for its biomedical actions in 
the treatment of various wounds including burns and ulcers254 and these ingredients vary in 
their physico-chemical properties depending on the plant species on which the bees feed as 
well as the climatic and variations in general vegetation.262 The main ingredients in honey are 
carbohydrates of which 95% are sugars, (mainly glucose and fructose) which form the building 
blocks for other more complex sugars present in quite small quantities. These sugars form 
during a chain of enzymatic (invertase, diastase, glucose oxidase and catalase) reactions 
occurring within the honeybee during the ripening of honey or by chemical action in the 
concentrated honey.263 Honey also contains various organic acids, such as gluconic acid, which 
make up just 0.5% of the total solids with pH  ranging from 3 to 4.5.Other acids in honey 
include formic, acetic, butyric, lactic, oxalic, succinic and tartaric acids.263 Another group of 
important constituents of honey are polyphenols which account for the natural antioxidants 
properties. Among these polyphenols, catechin, quercetin and taxifolin have been reported to 
have the highest anti-oxidation effects.264  
 
$QWLPLFURELDODFWLYLW\ 
The antibacterial activity of honey is reported against over 60 bacteria species including 
aerobes and anaerobes, Gram-negative, Gram-positive and some fungi. These include 
Pseudomonas aeruginosa, Staphyloccocus aureus, Candida albicans and Escherichia coli, , 
coagulase negative Staphylococci, Acinetobacter baumannii  Stenotrophomonas maltophilia, 
MRSA and VRE257-259.238-240 Furthermore, honey plays an important role in preventing biofilm 
formation.265 The high sugar content of honey was previously considered as the main 
antibacterial agent due to the osmotic action of sugars which deprive bacterial cells of water 
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vital for growth.266 However, dilution in water increased the antimicrobial efficiency of honey 
and further research later identified hydrogen peroxide as the main antimicrobial agent 267.248 
The antimicrobial properties of honey is attributed to the cumulative action of high sugar 
content, acidity (low pH),266 hydrogen peroxide268,269 and some phytochemicals, including 
flavonoids and phenolic acids. The flavonoid, pinocembrin has been identified as an 
antimicrobial factor270 possibly resulting from the ability of flavonoids to form complexes with 
soluble proteins and cell walls of bacteria. Phenolic acids such as methyl syringate are reported 
to possess antibacterial activity, however they only account for about 4% of the nonǦperoxide 
antibacterial activity of diluted honey.271 Furthermore, freshly extracted honey from the comb 
is known to have high levels of lysozyme which possesses antimicrobial action.272 Other 
important chemical factors such as volatiles, organic acids, lysozyme, beeswax, nectar, pollen 
and propolis are important for the antibacterial properties of honey.273  
Though there is no conclusive evidence of benefit in medical use of honey,255 honey 
dressings, gels and the pure liquid have been gaining in popularity, fueled by scientific reports 
on their medical benefits and occasional news accounts of the dramatic recovery of a patient 
with chronic wound. The mostly low quality of the evidence and the heterogeneous nature of 
the patient populations make it difficult to draw overall conclusions about the effects of honey 
as a topical treatment for wounds. However, from data collected in a recent Cochrane review, 
honey appears to heal partial thickness burns more quickly than conventional (polyurethane 
film, paraffin gauze, tobramycin-impregnated gauze, sterile linen) treatment whilst infected 
post-operative wounds healed more quickly than antiseptics and gauze.274 Honey dressings are 
available in various commercial preparations such as honey gel ointment, honey impregnated 
tulle dressings, honey impregnated calcium alginate dressings, and honey-based sheet hydrogel 
dressings (table 7).130,258,275,276  
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 Table 7. Commercially available honey products used in wound healing 
Commercial name Company Forms Honey type 
0*2Manuka 
Honey 
Manuka Health 
New Zealand Ltd Pure Honey Manuka honey 
Manuka Fill® Links Medical Sterile Manuka Honey Manuka honey 
Manuka IG® Links Medical Honey impregnated gauze Manuka honey 
6XUJLKRQH\ H&R Healthcare Pure Honey Bio-engineered honey 
TheraHoney® Medline Sheets, ribbon, gel Manuka honey 
Medihoney® Derma Sciences 
Hydrogel colloidal sheet, 
Honey colloid Dressing, 
calcium alginate dressings, 
gel and paste 
Manuka honey 
Activon® Advancis Medical Knitted viscose mesh dressing, pure honey Manuka honey  
Algivon® Advancis Medical Alginate ribbon and dressing Manuka honey  
Actilite® Advancis Medical 
Composite foam/silicone 
dressings, non-adherent 
viscose net dressing, 
Manuka honey  
 
Manuka honey is probably the most widely known honey used over centuries as a wound 
dressing. It is a mono-floral honey produced in New Zealand and Australia from the nectar of 
the PƗQXND tree (Leptospermum scoparium), plant which is endemic in parts of Australia and 
New Zealand. Manuka honey has been reported to exhibit antibacterial activity against a broad 
spectrum of bacteria including Staphylococcus aureus (including MRSA), Pseudomonas 
aeruginosa and VRE.277 The antibacterial properties of Manuka honey are principally, but not 
exclusively, due to methylglyoxal.278 Medihoney® Dressing (Derma Sciences, USA) was the 
first wound dressings based on active Manuka Honey to receive FDA approval for clinical use. 
According to the FDA, Medihoney® dressings are indicated for the management of light to 
moderately exuding wounds such as diabetic foot ulcers, venous or arterial leg ulcers, partial 
or full thickness pressure ulcers/sores, first and second partial thickness burns, traumatic and 
surgical wounds. 
A high-standardized synthetic antibacterial honey was developed by H&R Healthcare 
using a proprietary manufacturing process to produce precise levels of antimicrobial potency 
 35 
through steady delivery of oxygen free radicals. Surgihoney® is a licensed sterile product based 
on natural, organic honey from a variety of sources, which has been developed for wound care 
and as a prophylactic dressing for wounds. The antimicrobial activities mediated by hydrogen 
peroxide279 make Surgihoney® active against both Gram-positive and Gram-negative bacterial 
at very low concentration.280  
Due to their natural origin and the high purity, honey dressings have few 
contraindications, however, they should be avoided in patients with a known history of allergy 
to either honey or bee venom. It was also reported that patients with diabetes should have their 
blood sugar monitored as they may be at higher risk of hyperglycemia due to the high sugar 
content of honey.275 
 Propolis (honeybee glue) is another natural substance produced by honeybee useful in 
wound healing.281 It is a resinous mixture of botanical balsams and resins with digestive 
enzymes of bees used principally as a sealant in the hive. In traditional medicine, propolis is 
widely used for the treatment of various ailments including ulcer and wound healing. The 
presence of biologically active ingredients such as flavonoids, phenolic acids, terpenes, benzoic 
acids, amino acids and vitamins, impart to propolis an antioxidant, antimicrobial and immune-
modulatory action with a resultant acceleration of wound healing.281,282 Collagen-based films 
containing hydro-alcoholic extracts of two different varieties of propolis were studied by de 
Almeida et al. on dermal burn healing in a rodent model.283 These films significantly decreased 
the inflammatory severity improving the biological events associated with burn healing and 
seems to be a promising new dressing for wound occlusion and tissue repair.283 
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Sutures are biomaterial devices (natural or synthetic), usually used for mechanical 
wound closure to hold tissues together following surgery or trauma. Suturing in one of the most 
ancient wound healing techniques and although other methods for mechanical wound closure, 
such as staples, tape, and adhesive, have been developed over the years, sutures are still the 
most widely used materials.284 Sutures are generally categorized according to the type of 
material (natural or synthetic), the lifetime of the material in the body (absorbable or non-
absorbable) and the form in which they were made (braided, twisted, and monofilament). Each 
type of suture has different characteristics, properties and surgical application, as reported by 
Pillai and Sharma.284 Despite the differences in materials and performance, the main goal of 
sutures is the approximation of the epithelial portion of the wound, maintaining the tensile 
strength across the wound until tissue tensile strength is adequate. To exert this action, sutures 
are in direct contact with the wound, and for this reason can represent a useful scaffold for local 
delivery of active molecules to the wound. 
 Despite the significant advances in aseptic principles of surgery and the ongoing 
improvement of minimal invasive surgery, surgical site infections (SSIs) are still the major 
source of prolonged illness and death in surgical patients.285 SSIs occur when pathogenic 
organisms (usually members of the Staphylococci family) proliferate in surgical wounds, 
resulting in the impeding of wound healing, separation of the wound edges (dehiscence), and 
increase in the risk of abscess in deeper wound tissues. At least 5% of patients undergoing 
surgery develop SSIs which increases the duration of hospitalization by 20-fold and results in 
a greater risk of readmission and higher healthcare costs.286 Sutures can be a source of surgical 
wound contamination because of their non-shedding surface to which bacteria can adhere, form 
biofilms and potentiate SSIs. The presence of foreign materials in a wound enhances the 
susceptibility of surrounding tissues to infection and in the presence of sutures only 100 colony-
forming units (CFU)/mg are necessary to produce infection.287 Bacteria can also contaminate 
the suture itself making local mechanisms of wound decontamination become ineffective.  
 To reduce bacterial adherence and colonization of suture materials, sutures impregnated 
or coated with antibacterial agents have been developed. Suture materials, especially braided 
or twisted sutures, are frequently coated to facilitate their handling properties and the 
incorporation of antibiotic drugs or silver ions is one of the approaches adopted to impart 
antimicrobial activity. Ideally, an antimicrobial-impregnated suture should prevent bacterial 
adhesion and biofilms formation using antiseptics drugs with a rapid, potent and broad 
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microbiocidal spectrum, long-lasting effects and no risk of developing antimicrobial resistance. 
Furthermore, they should be biocompatible with medical products, not impair healing 
processes and be well tolerated in wounds with no toxicity or systemic absorption. Even though 
the development of an antibacterial surgical suture has been under consideration since the early 
1980s, the first commercial antimicrobial suture, Polyglactin 910 suture loaded with triclosan 
(Vicryl Plus®), was only approved for clinical use by the FDA in 2002. Different polymeric 
triclosan-coated sutures are actually on the market, but clinical studies are still unclear about 
the real effectiveness of these antibacterial sutures.286 The main disadvantage of triclosan is that 
its widespread use in non-medical products such as cosmetics, soaps and detergents, has 
resulted in a rise in triclosan-resistant bacteria.  
 The enormous market potential of this device makes research into anti-microbial 
surgical sutures very attractive and as a result, new potential alternatives to triclosan are 
currently under investigation. A suitable alternative to overcome triclosan bacterial resistance 
is chlorhexidine, a wide spectrum antimicrobial agent principally used as oral antiseptics. 
Chlorhexidine coated sutures were recently successfully developed using different fatty acids 
as coating material to achieve a high anti-microbial efficacy and biocompatibility.288 In 
addition silver,289 and AgNPs,290 have been proposed for suture coating, showing an anti-
inflammatory and antimicrobial activities suitable for potential clinical application.  
This new generation of suture materials when used to deliver GFs, enzymes or other 
biomacromolecules directly to the wound site, can result in significant improvement beyond 
the currently employed surgical procedures. Several studies have demonstrated the possibility 
of  incorporating GFs into polymeric bioadsorbable coating materials. Bigalke et al. 
investigated a poly(L-lactide) (PLLA) coating on a commercially available suture for the 
delivery of VEGF.291 The authors obtained a well-tuned VEGF release from the suture wire, 
which resulted in an increased vascularization and consequent wound healing enhancement. 
Other GFs, such as IGF-1 or growth differentiation factor-5, have been investigated and 
observed to promote healing in rat models of anastomoses292 and tendon repair293 respectively. 
An innovative approach for GFs release from a suture wire was proposed by Reckhenrich et 
al. who prepared a surgical suture filled with adipose-derived stem cells (ADSCs) to provide 
pro-regenerative features and allowed the treatment and the fixation of the wound in one single 
step.294 The incorporation of ADSCs into the inner core of the suture did not affect their 
viability and the cells remained attached to the suture materials after implantation, constantly 
releasing cytokine and GFs. However, the low mechanical properties of this ADSCs-loaded 
suture (due to the filling procedure), restrict their use only to elastic tissues.  
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Tissue degradation is a problem that often occurs at the repair site, resulting in increased 
risk of post-operative leakage. Implantation of a foreign material into the tissues invariably 
evokes a reaction, characterized by an elevated production of MMPs, an enzyme that degrades 
the extracellular matrix, allowing the suture to cut through the tissue and thus contributes to 
repair-site elongation and gap formation. Medicated sutures coated with doxycycline, an MMP 
inhibitor, were used to improve the suture-holding capacity in tendon repair procedure during 
early repair of collagenous tissues.295  
Though coating has been shown to be an easy procedure to prepare drug-loaded sutures, 
such fabrication procedures FDQ KDYH QHJDWLYH HIIHFWV RQ WKH VXWXUH¶V PHFKDQLFDO VWUHQJWK
especially at the site of the knot, which is essential for effective wound closure. Moreover, it 
has been shown that suture coatings can lead to physical disruption of the bioactive reagent 
during the mechanically bearing suturing process.296 To overcome these limitations, new 
strategies have been developed. For example, , Lee et al.297 prepared a composite surgical 
dressing by assembling together a drug loaded biocompatible polymeric sheet with a surgical 
suture material, which enabled controlled delivery of an analgesic drug,  and is already in 
clinical use. The drug loaded suture showed good biocompatibility and mechanical properties 
comparable to those of the original surgical suture and by modifying only the polymeric sheet, 
it is possible to tune the drug release for up to six days, effectively relieving the pain at the 
surgical site during the period of wound healing. Drug-eluting electrospinned fibers have been 
proposed for the local delivery of antibiotics298 and local anesthetics299 but their weak 
mechanical properties and difficulty of scaling up, make these sutures difficult to be applied in 
clinical settings.  
 Extrusion processes are usually employed for the large-scale synthetic production of 
sutures because they allow a precise and controlled manufacturing process resulting in uniform 
and reproducible properties. However, the high temperature required to melt the polymers can 
degrade the bioactive molecules, limiting the application of this process in the biomedical field. 
To protect the drugs from degradation, inclusion of active drugs into an organic or inorganic 
microstructure that can be dispersed in the polymeric matrix during the extrusion phase, has 
been proposed.300 Medicated sutures containing an anti-inflammatory agent loaded into an 
inorganic layered material has already been developed, showing the potential of this 
approach.301  
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For wounds where there has been excessive skin loss or damage, in which both epidermal 
and dermal skin layers are lost, wound healing using only dressing materials or delivery of 
active agents alone is not viable. Therefore, alternative solutions using either artificial or 
bioengineered skin substitutes are required to allow the necessary regeneration and replacement 
of lost tissue. According to Mansbridge, tissue engineered skin substitutes, function effectively 
due largely to the ability of fibroblasts and keratinocytes to spontaneously form three 
dimensional structures similar to skin, though other cell types have been included which allow 
a wide range of properties naturally displayed by normal intact skin.302 Limova303 in 2010, 
made the following poignant summary about these highly advanced wound healing products: 
³extensive skin loss and chronic wounds present a significant challenge to the clinician. With 
increased understanding of wound healing, cell biology and cell culture techniques, various 
synthetic dressings and bioengineered skin substitutes have been developed. These materials 
can protect the wound, increase healing, provide overall wound coverage and improve patient 
care. The ideal skin substitute may soon become a reality´6LQFH WKLVRbservation, several 
advances have been made in this field and skin substitutes represent a significant improvement 
over modern moist dressings and advanced drug delivery dressings. In addition, they also 
provide a more convenient alternative to the harvesting and use of skin grafts from healthy 
areas of the body as these are very painful and self-defeating because of the need to create a 
wound elsewhere in the body.  
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Unlike dressing or direct regenerative approaches, tissue engineered skin substitutes 
comprise fabricated biomaterial polymer matrix (such as collagen) which acts as scaffolds for 
engineered skin substrates which grow to actively replace lost tissue.  The scaffolds possess 
mechanical and anatomic characteristics ideally approaching that of the tissue (normal dermis) 
which they are to replace.304 The scaffold materials gradually degrade within the body, leaving 
behind a matrix of connective tissue with the appropriate structural and mechanical properties. 
Hartmann Fritsch et al305 have reported on reinforced collagen hydrogels as dermal-epidermal 
skin substitutes in rats. Their results showed that the skin substitutes developed into a 
homogeneous and well-stratified epidermis over the entire surface of the grafts, with a 
continuous basement membrane and dermo-epidermal junction. An antibacterial scaffold was 
prepared by electrospinning of a solution comprising dextran, polyurethane and ciprofloxacin 
HCl (CIP HCl) drug.306 The results showed favorable interaction between fibroblast cells and 
the scaffolds, in particular the ciprofloxacin loaded matrices.306 Jin et al307 also showed the 
potential of electrospinned nanofibers containing polycaprolactone and the plant extract of 
Memecylon edule as substrates for skin tissue engineering in burn wounds. 
Several tissue engineered skin substitutes are available on the market but these have been 
previously reviewed,1 and the reader is referred to this review for relevant references and more 
detailed discussion. However, there has been several published literature on the subject 
including newer models and advanced characterization of these wound healing systems, most 
driven by recent advances in tissue regeneration approaches including plastic surgery.  
Michael et al.308 proposed a mice model for the functional characterization and testing of 
skin substitutes using the dorsal skin fold chamber of mice. They inserted commercial dermal 
construct, (Matriderm®, MedSkin Solutions Dr. Suwelack AG, Germany) covered with 
collagen gel, into full thickness wounds in the skin fold chambers and showed good integration 
into the nearby healthy skin and wound epitheliazation within 11 days. They suggested that 
such a model could be useful in situations where a lack of sufficient areas for obtaining split 
thickness skin grafts becomes an issue.308 Martin et al.309 investigated the effect of tissue-
engineered biological dressing matrices loaded with human in vitro-differentiated adipocytes 
and ADSCs by evaluating re-epithelialization, granulation tissue formation and 
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neovascularization of full-thickness cutaneous wounds in fluorescent epidermis of a mouse 
model.309 It was demonstrated that the tissue engineered treated wounds showed significantly 
faster wound closure than control wounds without the dressing application over an 18-day 
period. They also showed by non-invasive imaging of GFP-expressing keratinocytes, that the 
rate at which the wounds re-epithelialized were similar for both groups with the treated wounds 
exhibiting thicker collagen enriched granulation tissues. It was concluded from this study that 
composite engineered substitutes comprising both adipocytes and ADSCs have potential to 
stimulate cutaneous wound healing when applied as temporary dressings. Table 8 summarizes 
other reported uses of tissue engineered skin substitutes for treating various types of wounds 
including chronic wounds. 
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Table 8. Selected tissue engineered substitutes reported in the literature for application to different wound types 
including chronic wounds. 
Matrix  Construct source Author/Reference 
Collagen Human dermis Netchiporouk et al.310  
Collagen-elastin Human subcutaneous adipose tissue Keck et al.311  
Synthetic electrospun 
polylactide (PLA) 
Finely minced split thickness human 
skin 
Sharma et al.312  
Collagen Living skin substitute Wahab et al.313  
EGF incorporated 
gelatin microspheres 
Bone-marrow-derived mesenchymal 
stem cells (BM-MSCs) 
Huang et al.314  
3D fibrin / collagen 
type 1-hydrogels 
Human dermo-epidermal skin 
substitutes (DESS) 
Klar et al.315  
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A significant number of recent research investigations have demonstrated the importance of 
oxygen in the field of chronic wound healing.316,317 Oxygen plays an essential role in support 
of cellular processes and infection control, and it is commonly accepted that inadequate cellular 
oxygenation and perfusion leads to impaired wound healing, triggering wound maceration and 
delayed healing.318 Chronic wounds, in particular diabetic ulcers, usually have a compromised 
circulation due to a disruption of the blood flow or edema, which decrease or prevents oxygen 
delivery to healing cells.  
Hyperbaric oxygen therapy was originally designed for use in decompression illness in 
deep sea divers and been used as an adjunct in wound healing for 40 years.319 This treatment 
involves placing the patient in a sealed chamber where 100% oxygen is pressurized to between 
1.5 and 3 atmospheres absolute (ATA) for 60 to 120 minutes over a course of multiple 
treatments. Hyperbaric oxygen significantly increases the oxygen saturation of plasma, raising 
the partial pressure (PaO2) available to tissues, which in turn causes vasoconstriction. This 
vasoconstriction on the arterial end reduces capillary pressure, which promotes fluid absorption 
into the venous system thereby reducing edema, as well as causing an increase in hyper-
oxygenated plasma to the tissues. Tissue repair processes such as collagen elongation and 
deposition and bacterial killing by macrophages are dependent upon oxygen, therefore 
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increased levels in wound areas that already have impaired perfusion, serve to facilitate wound 
healing. The application of hyperbaric oxygen is particularly advantageous in patients with 
diabetic foot ulcers where it is associated with significantly higher rates of wound healing and 
could significantly reduce the risk of major amputation.316,320,321 In addition to immediate 
assistance in healing, hyperbaric oxygen also has a role in long-term wound improvement, 
perhaps due to the realization of the full effects of neovascularization.322  
Topical wound oxygen therapy is an alternative method of administering oxygen to a 
wound, where 100% humidified, pressurized oxygen is directly applied to the surface of an 
open, ischemic wound in order to increase the local oxygen levels in the tissue. This route of 
administration involves injecting pure oxygen into a portable inflatable bag, which encases the 
wound area. Topical oxygen therapy, used as an adjunct to other therapies, has been shown to 
be effective for wound healing,323,324 and the low costs, greater portability, and reduced risks 
of oxygen toxicity make this approach more beneficial than hyperbaric oxygen.316 However, 
both these therapeutic approaches are time consuming and inconvenient for the patient due the 
required immobility during treatment.  
 The use of a therapeutic wound dressing to deliver oxygen directly to the cells may be 
an interesting strategy as it is more cost effective, portable and presents the possibility of 
promoting more rapid wound healing. Topically delivered dissolved oxygen has no deleterious 
effects and stimulates beneficial effects even on intact, non-wounded skin.325 Furthermore, 
these dressings maintain some of the properties of an ideal1 wound dressing providing all the 
desirable useful features to promote effective wound healing. Different approaches have been 
proposed to obtain local oxygen release from wound dressings. Oxygen can be stored inside 
the dressing between an occlusive upper layer and a lower permeable film, which allows the 
dressing to supersaturate the wounGIOXLGZLWKUHJHQHUDWLYHR[\JHQIRUGD\V7KHVH³R[\JHQ
UHVHUYRLUGUHVVLQJV´DUHIRDPbased dressings containing oxygen micro-bubbles which begin 
WR³GLVVROYH´ZKHQWKHIRDPLVPRLVWHQHGZLWKH[XGDWHDQGRQFHGLVVROYHGR[\JHQFDQHDVLO\
travel according to the oxygen gradient across poorly perfused tissue. Transcutaneous 
dissolved oxygen was demonstrated to promote wound healing and limit necrosis, thus 
decreasing the healing time and the pain at donor sites.326,327 
Oxyzyme® dressing (Crawford Healthcare Ltd, UK) is an enzyme-activated hydrogel 
dressing developed to support the wound healing process by releasing oxygen and also 
impeding microbial growth due to the release of iodine. The dressing is a two component 
advanced hydrogel containing glucose oxidase to generate hydrogen peroxide and a halide 
iodide to generate hypoiodite which leads to iodine production. When the dressing is removed 
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from its airtight package and the two layers are brought into contact with each other, the oxidase 
enzyme within the top layer is ready to start its reaction with oxygen. The enzyme activation 
generates a flow of hydrogen peroxide in the dressing. When applied on the wound, the 
hydrogen peroxide is converted to water and dissolved oxygen by serum catalase in the 
wound.328 The wound bed becomes rich in locally available oxygen, with all of its associated 
benefits, to work in harmony with the antimicrobial effects of the iodine and various other 
optimizing effects of the dressing. A similar product (Iodozyme® Crawford Healthcare Ltd, 
UK) has been developed for patients with chronic infection or bacterial bioburden using the 
same principle and differs only in the amount of iodine produced. Both dressings have lower 
levels of iodine if compared with other iodine based dressings, but have similar antimicrobial 
properties.328  
 
Table 9. Commercially available topically delivered dissolved oxygen dressing. 
 
Commercial 
name 
Company Form Oxygen delivery system References 
Oxyzyme® 
Crawford 
Healthcare Ltd, 
UK 
2 part sterile hydrogel 
dressing  
Enzyme-activated 
in situ oxygen 
production 
Moffatt et al.328  
OxyBand® 
OxyBand 
Technologies 
Inc, USA 
Self-contained multiple 
layers hydrocolloid 
dressing. The top layer is 
a waterproof barrier film 
Oxygen pre-filled 
wound dressing Lairet et al.
326
  
Oxygenesys® Halyard Health Inc, USA Adsorbent foam dressing 
Oxygen pre-filled 
wound dressing 
Kellar et 
al.325,327  
 
8.2 1HJDWLYHSUHVVXUHZRXQGWKHUDS\ 
 Negative-pressure wound therapy (NPWT) also known as topical negative-pressure 
therapy or vacuum-assisted closure has become an integral part of modern wound care practice 
and is used routinely in hospitals throughout the world, where it is estimated that 300 million 
acute wounds are treated globally each year.329-331 Morykwas et al. first reported on this NPWT 
using an open-cell foam dressing with the application of a controlled sub-atmospheric pressure 
for the treatment of acute and chronic wounds.332,333 NPWT promotes wound healing by 
applying a vacuum through a special sealed dressing. The continued vacuum draws out fluid 
from the wound and increases blood flow to the area.  
Preclinical and clinical studies have confirmed that NPWT provides a moist wound 
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healing environment, drains exudate, reduces tissue edema, contracts wound edges, 
mechanically stimulates the wound bed, alters blood flow in and around the wound edges, and 
stimulates angiogenesis and the formation of granulation tissue.332-334 The beneficial effects of 
NPWT on wounds are mediated by multiple mechanisms, which together contribute to the 
observed clinical effects. However, little is known about the influence of different NPWT 
settings on their biological activity in the wound.  
The dressings used for the technique include open-cell foam dressings and gauze with 
a pore range of 400-ȝPFXWWRILWWKHZRXQGVXUIDFHDQGVHDOHGZLWKDQRFFOXVLYHGUHVVLQJ
intended to contain the vacuum at the wound site. The open-cell polyurethane foam dressing 
enables equal distribution of the negative pressure over the entire wound bed, and also allows 
exudate to flow freely for collection and removal in the canister. The foam can be used to pack 
open cavity wounds and can also be cut to size to fill underlying areas. The pore size of the 
NPWT dressing foam dressings are larger than other foam dressings to maximize tissue 
growth.332  The first device for NPWT introduced on the market was the V.A.C.® Therapy 
System (KCI, USA) and until 2003, was the only commercially available system. With the 
affirmation of the method, different devices were introduced with the main difference between 
them being the type of dressing used to fill the wound (foam or gauze).  
NPWT can be used to achieve a variety of treatment goals, but cannot replace surgical 
procedures. The therapeutic efficacy depends on the patient and the characteristics of the 
wound,329 and usually may allow a wound to progress to the point at which a less invasive 
procedure is possible.335 NPWT can also be used in cases of infected wounds, as an adjuvant 
to an appropriate systemic antibiotic therapy. The application of negative pressure creates a 
hypoxic environment at the wound bed/dressing interface reducing the bacterial count at the 
wound bed up to 1,000 times after four days of treatment.336 Since its mode of action is not 
selective, NPWT is effective against difficult infections such as MRSA and drug-resistant 
bacterial strains. Commercially, a IRDPGUHVVLQJFRDWHGZLWKVLOYHU*UDQX)RDP.&,86$
was developed to impart additional antimicrobial properties.337  
8.3 3K\VLFDOWKHUDSLHVLQZRXQGKHDOLQJ 
8.3.1 (OHFWULFDOVWLPXODWLRQ 
 Electrical stimulation (ES) is believed to aid in wound healing for the treatment of both 
acute and chronic wounds by imitating the natural electrical current that occurs in injured skin. 
The body naturally creates and uses electrical energy that aids in the recruitment of cells 
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necessary for healing through a process called galvanotaxis or electrotaxis.338 The undamaged 
skin contains an electro-potential of 30 mV to 100 mV between the stratum corneum and the 
dermis, however, when the epithelial cells break down due to injury, this difference in potential 
is lost. This loss in potential is the earliest indicator stimulus signal to initiate cell migration 
and re-epithelialization, and many epithelial cells including human keratinocytes have the 
ability to detect electric fields and respond with directed migration.339 In addition, other cell 
types such as neutrophils, macrophages and fibroblasts seem to be sensitive to ES, increasing 
the migration rate.340 Some experiments indicate that when the electric field is removed, the 
wound healing rate is 25% slower.338  
The clinical evidence for the application of different types of ES to enhance cutaneous 
wound healing has recently been summarized by Ud-Din and Bayat.341 ES has been shown to 
have beneficial effects on the different phases of cutaneous wound healing in both chronic and 
acute wounds, concluding that the application of an electric potential on the wounded skin 
results in a significant improvement in wound area reduction or accelerated wound healing 
compared to the standard methods of care as well as improved local perfusion.341 Additionally, 
ES has action against bacterial infection, a major cause of impaired wound healing.342 Usually, 
the ES is applied using an external device by placing the electrodes on the skin, and often, 
directly onto the wound. Several different modalities of ES have been described for each wound 
type with varying voltages, currents, electrical waveforms, modes and length of time of 
application, and no device-related complications or adverse effects have been reported in the 
existing literature, indicating that the therapy is safe and easy to use.341  
Bioelectric dressings (BED) are emerging as a useful method of delivering ES to the 
wound site. This device combines the beneficial wound repair characteristics of both an 
occlusive dressing and an electrical gradient, and simultaneously utilizes two separate 
mechanisms that have been shown to aid wound healing. One of the first BEDs introduced on 
the market was PosiFect®RD (Biofisica UK Ltd), which contains a miniature electrical circuit 
that delivers a micro-current derived from two lithium non-rechargeable coin cell batteries to 
the wound bed for a minimum of 48 hours. This device has been demonstrated to have 
potentially multiple positive effects on all phases of wound healing, in particular in treating 
chronic wounds that have previously been non-responsive to treatment.343 A new bioelectric 
bandage based RQWKH3526,7WHFKQRORJ\ZDVapproved by the FDA to treat partial and full-
thickness wounds. Its dressing form, Procellera® (Vomaris Wound Care Inc., USA) is a woven 
metallic BED (figure 4A) activated by wound exudate, thereby generating  a sustained electric 
stimulation of 2 - 10 mV produced by micro-batteries of silver (Ag) and zinc (Zn) metals, 
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which are inside a woven material (figure 4B). After its application, the wound is covered with 
an overlying dressing to keep the wound moist and the dressing active for up to 30 days. The 
application of an electric field generated by Ag/Zn BED increases keratinocyte migration, a 
critical event in wound re-epithelialization, via redox-dependent processes,344 resulting in 
faster wound epithelialization and improved scar appearance.345,346 In addition, it showed 
antimicrobial properties against antibiotic-sensitive strains and multiple antibiotic-resistant 
strains of wound pathogens,347 even when these bacterial strains formed a polymicrobial 
biofilm.348 Procellera® can be easily cut to the size of the wound and conforms to irregular 
surfaces and to wound edges. The main advantage of these devices is that they are wire-less 
with no need for an external power source and can be applied and changed easily without the 
requirement for someone specially trained in ES.  
 
.  
 
Figure 4. Schematic diagram of the design, application (A), and electric fields (B) generated by Procellera® 
bioelectric dressing.344  
 
8.3.2 3XOVHGHOHFWURPDJQHWLFWKHUDS\ 
The use of pulsed radio-frequency electromagnetic field (PEMF) therapy, has shown 
notable success in healing of chronic wounds. PEMF is a non-ionizing energy at the shortwave 
radio frequency band of the electromagnetic spectrum, commonly at a frequency of 27.12MHz 
and widely used in the field of orthopedics. This therapy is non-invasive and can also be applied 
to the wound area through wound dressings to aid healing of chronic wounds such as venous 
leg ulcers.349 Furthermore, it has been reported that PEMF can also provide analgesic benefit 
to patients following surgery or other soft tissue trauma, with few reports of side 
effects.350PEMF devices such as Provant® (Regenesis Biomedical, USA) are already used for 
the treatment of chronic ulcers and postoperative pain, and a new wearable PEMF device was 
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successfully used for treatment and healing of four patients with non-healing wounds.351 
However, though the application of electromagnetic fields to the wound area significantly 
improved both diabetic and normal wound healing in mice,352 there is no clinically relevant 
evidence to show that electromagnetic therapy increases the rate of healing of venous leg ulcers 
in patients, and further research is therefore needed.349,353  
 
8.3.3 /RZOHYHOODVHUWKHUDS\ 
 Low-level laser therapy (LLLT) is a medical procedure that uses red and near-infrared 
monochromatic light (600 - 1000 QPWRHQKDQFHWKHERG\¶VQDWXUDOKHDOLQJSURFHVVHV:KHQ
the light source is placed in contact with the skin, the light energy (photons) penetrates into the 
tissue, where it alters the healing process at a cellular level. It is not exactly clear how low-
level laser therapy works, but some reports354 suggest that photons are absorbed by the 
mitochondria and stimulate more ATP production and low levels of reactive oxygen species 
(ROS). These then activate transcription factors such as NF-ț%WRLQGXFHPDQ\JHQHWUDQVFULSW
products which provide the beneficial effects.354 The way light interacts with the biological 
tissues will depend on the characteristics and parameters of light devices but there is evidence 
that coherent (laser) and non-coherent (LED) light produce similar healing effects on tissues.355 
LLLT has been reported to promote osteogenesis,356 wound healing,334 and the eradication of 
bacterial biofilms.335 Currently, a large number of basic studies have reported bio-stimulative 
effects of LLLT on different types of chronic wounds both in animal models and in humans, 
but until now there is insufficient evidence to establish the usefulness of LLLT as an effective 
tool in wound care management.357,359,360 Further work is therefore required to confirm its 
clinical effectiveness in a conclusive way including randomised clinical trials.  
 49 
9 &21&/8',1*5(0$5.6 
 
Chronic wounds and other difficult to heal wounds have significant health, social and 
economic burdens on both patients and society in general and therefore of current topical 
interest worldwide.  
In this review, we have covered the current state of the art in chronic wound healing 
technologies involving the active treatment of these wounds, with emphasis on advanced 
therapeutically active systems and methods for healing of chronic and other difficult to heal 
wounds. The driving forces for the development of advanced dressings as improvements over 
currently used traditional and modern moist dressings, the evolution of the different advanced 
wound dressings reported in the literature and available commercially, have also been 
discussed. The major driving forces include the rise in an aging population and therefore 
increased incidence of pressure and venous leg ulcers, increase in obesity and associated type 
II diabetes, linked to diabetic chronic ulcers as well as the rise of super antibiotic resistant 
microorganisms (mainly bacteria) all of which increase the risk of delayed wound healing and 
potential morbidity (including amputations) and in severe cases, mortality. Other driving forces 
include the need to reduce cost to National Health Providers, by reducing hospital stays and 
nursing staff time spent with chronic wound patients. 
The review has covered many advanced wound dressings including biological dressings 
from natural biomaterial polymers (e.g. chitosan, collagen and hyaluronic acid), medicated 
modern dressings using agents such as antimicrobials (antibiotics, silver, PHMB, antimicrobial 
peptides) biological based dressings (comprising mainly GFs, stem cells, nucleic acids and 
other genetic materials), tissue engineered skin substitutes, dressings containing naturally 
derived wound agents such as Aloe and honey as well as more recent advances in NPWT, 
oxygen related dressings, electrical stimulation and laser therapy. Several challenges still 
remain in tackling the problems associated with chronic wounds and it is clear that even single 
advanced dressings and other advanced physical wound healing procedures, do not always 
address the problems encountered in chronic wounds for every single patient and therefore a 
combination of the above mentioned advanced systems will be required.  
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It is plausible that this will be the way forward in future developments for an ideal 
advanced dressing that will tackle the problems of chronic wounds including pain and 
inflammation, odor, infection caused by resistant bacteria, delayed healing and associated costs 
to health systems and populations worldwide. This is important given the many phases of 
wound healing and differences in complications observed in different patients. Therefore, a 
multi-targeted approach appears to be the best way forward and it is hoped that this review has 
contributed towards identifying the critical factors that need to be tackled to make this a reality 
in the near to medium term future. 
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